<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer New York</PublisherName>
    <PublisherLocation>New York, NY</PublisherLocation>
    <PublisherImprintName>Springer</PublisherImprintName>
  </PublisherInfo>
  <Book Language="En">
    <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
      <BookID>978-1-60327-829-4</BookID>
      <BookTitle>Drug Management of Prostate Cancer</BookTitle>
      <BookDOI>10.1007/978-1-60327-829-4</BookDOI>
      <BookTitleID>158057</BookTitleID>
      <BookPrintISBN>978-1-60327-831-7</BookPrintISBN>
      <BookElectronicISBN>978-1-60327-829-4</BookElectronicISBN>
      <BookChapterCount>37</BookChapterCount>
      <BookCopyright>
        <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
        <CopyrightYear>2010</CopyrightYear>
      </BookCopyright>
      <BookSubjectGroup>
        <BookSubject Code="SCH" Type="Primary">Medicine &amp; Public Health</BookSubject>
        <BookSubject Code="SCH33160" Priority="1" Type="Secondary">Oncology</BookSubject>
        <BookSubject Code="SCH62002" Priority="2" Type="Secondary">Urology</BookSubject>
        <BookSubject Code="SCH33002" Priority="3" Type="Secondary">Internal Medicine</BookSubject>
        <SubjectCollection Code="SUCO11650">Medicine</SubjectCollection>
      </BookSubjectGroup>
    </BookInfo>
    <BookHeader>
      <EditorGroup>
        <Editor AffiliationIDS="AffID1">
          <EditorName DisplayOrder="Western">
            <GivenName>William D.</GivenName>
            <FamilyName>Figg</FamilyName>
          </EditorName>
          <Contact>
            <Phone>301402-3622</Phone>
            <Fax>301402-8606</Fax>
            <Email>wdfigg@helix.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID2">
          <EditorName DisplayOrder="Western">
            <GivenName>Cindy H.</GivenName>
            <FamilyName>Chau</FamilyName>
          </EditorName>
          <Contact>
            <Email>chauc@mail.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID3">
          <EditorName DisplayOrder="Western">
            <GivenName>Eric J.</GivenName>
            <FamilyName>Small</FamilyName>
          </EditorName>
          <Contact>
            <Phone>415/353-7171</Phone>
            <Email>smalle@medicine.ucsf.edu</Email>
          </Contact>
        </Editor>
        <Affiliation ID="AffID1">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID2">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID3">
          <OrgDivision>School of Medicine, Dept. Urology</OrgDivision>
          <OrgName>University of California, San Francisco</OrgName>
          <OrgAddress>
            <Street>Divisadero Street 1600</Street>
            <City>San Francisco</City>
            <Postcode>94115</Postcode>
            <State>California</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </BookHeader>
    <Part ID="Part2">
      <PartInfo OutputMedium="All" TocLevels="0">
        <PartID>2</PartID>
        <PartNumber>Part I</PartNumber>
        <PartSequenceNumber>2</PartSequenceNumber>
        <PartTitle>Hormone Therapy</PartTitle>
        <PartChapterCount>9</PartChapterCount>
        <PartContext>
          <BookID>978-1-60327-829-4</BookID>
          <BookTitle>Drug Management of Prostate Cancer</BookTitle>
        </PartContext>
      </PartInfo>
      <Chapter ID="Chap10" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
          <ChapterID>10</ChapterID>
          <ChapterNumber>Chapter 10</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-829-4_10</ChapterDOI>
          <ChapterSequenceNumber>10</ChapterSequenceNumber>
          <ChapterTitle Language="En">Pharmacogenetics of the Androgen Metabolic Pathway</ChapterTitle>
          <ChapterFirstPage>109</ChapterFirstPage>
          <ChapterLastPage>121</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2010</CopyrightYear>
          </ChapterCopyright>
          <ChapterHistory>
            <RegistrationDate>
              <Year>2010</Year>
              <Month>4</Month>
              <Day>16</Day>
            </RegistrationDate>
            <OnlineDate>
              <Year>2010</Year>
              <Month>8</Month>
              <Day>3</Day>
            </OnlineDate>
          </ChapterHistory>
          <ChapterGrants Type="Regular">
            <MetadataGrant Grant="OpenAccess"/>
            <AbstractGrant Grant="OpenAccess"/>
            <BodyPDFGrant Grant="Restricted"/>
            <BodyHTMLGrant Grant="Restricted"/>
            <BibliographyGrant Grant="Restricted"/>
            <ESMGrant Grant="Restricted"/>
          </ChapterGrants>
          <ChapterContext>
            <PartID>2</PartID>
            <BookID>978-1-60327-829-4</BookID>
            <BookTitle>Drug Management of Prostate Cancer</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>Francine</GivenName>
                <GivenName>Zanchetta</GivenName>
                <GivenName>Coelho</GivenName>
                <FamilyName>Marques</FamilyName>
              </AuthorName>
            </Author>
            <Author AffiliationIDS="Aff1_10" CorrespondingAffiliationID="Aff1_10">
              <AuthorName DisplayOrder="Western">
                <GivenName>Juergen</GivenName>
                <GivenName>K.</GivenName>
                <GivenName>V.</GivenName>
                <FamilyName>Reichardt</FamilyName>
              </AuthorName>
              <Contact>
                <Email>jreichardt@med.usyd.edu.au</Email>
              </Contact>
            </Author>
            <Affiliation ID="Aff1_10">
              <OrgDivision>Plunkett Chair of Molecular Biology (Medicine)</OrgDivision>
              <OrgName>The University of Sydney</OrgName>
              <OrgAddress>
                <City>Sydney</City>
                <State>NSW</State>
                <Country>Australia</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1_10" Language="En" OutputMedium="All">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">Androgens are steroid hormones responsible for the development, growth, and maintenance of masculine characteristics, including the prostate. It has been known for decades that they are very important in the development and progression of prostate cancer (CaP). The most common treatment for CaP is based on androgen deprivation therapy. There are preventive strategies that seem to act on the same pathway, such as finasteride, dutasteride, selenium, and vitamin E. Various genes in androgen synthesis and metabolism have been studied in relation to the predisposition and progression of CaP, such as several members of the steroid 5α-reductase (SRD5A), 3β-hydroxysteroid dehydrogenase (HSD3B), and 17β-hydroxysteroid dehydrogenase (HSD17B) families, androgen receptor (AR), cytochrome P450 17 (CYP17), and cytochrome P450 19A1 (CYP19A1). However, most of them have not been biochemically evaluated, or the studies are contradictory. For example, the expression reports about CYP19A1 indicate positive and negative results for both benign and carcinogen prostate. There is a need for extensive research in response to prostate carcinoma prevention as well as treatment. Studies have shown that other genes, such as the solute carrier organic anion transporter 1B3 (SLCO1B3), and gene fusions may be involved in CaP personalized medicine, but the results are inconclusive since the number of reports is small, and there is a lack of replication in larger samples. Pharmacogenetics is the key to future medicine, especially for cancer and personalized medicine. More investigations should be done to evaluate the role of these genes in prostate cancer biochemistry, prevention, progression, development, and treatment.</Para>
          </Abstract>
          <KeywordGroup Language="En" OutputMedium="All">
            <Heading>Keywords</Heading>
            <Keyword>Multifactorial disease</Keyword>
            <Keyword>Prostate cancer</Keyword>
            <Keyword>Androgen</Keyword>
            <Keyword>Treatment</Keyword>
            <Keyword>Prevention</Keyword>
            <Keyword>Pharmacogenomics</Keyword>
          </KeywordGroup>
        </ChapterHeader>
        <Body>
          <Section1 ID="Sec1">
            <Heading>Androgens and Prostate Cancer</Heading>
            <Para TextBreak="No">Androgens are steroid hormones that are widely accepted to be responsible for the development, growth, and maintenance of the prostate (Fig. <InternalRef RefID="Fig1">10.1</InternalRef>). Although they can be formed by peripheral tissues, such as skin and prostate, the adrenal gland and the testes are fundamentally responsible for their production in males. The pathway comprising the formation of androgens is well described (Fig. <InternalRef RefID="Fig1">10.1</InternalRef>). Testosterone, the major male androgen in circulation, and dihydrotestosterone (DHT), the principal androgen in tissues and the most potent one, are the two most important androgens in adult men. They both bind to the androgen receptor (AR), which mediates the physiologic effects of androgens by binding to specific DNA sequences that influence the transcription of androgen-responsive genes (for review, see [<CitationRef CitationID="CR1_10">1</CitationRef>]). DHT has a higher binding affinity for AR and induces transcriptional activity 2–10 times more than testosterone [<CitationRef CitationID="CR2_10">2</CitationRef>]. The importance of these hormones in male sexual differentiation is supported by the clinical observation that the deficiency of steroid 5α-reductase (SRD5A) or 17β-hydroxysteroid dehydrogenase (HSD17B) can lead to male pseudohermaphroditism (for review, see [<CitationRef CitationID="CR3_10">3</CitationRef>]).<Figure Category="Standard" Float="Yes" ID="Fig1">
                <Caption Language="En">
                  <CaptionNumber>Fig. 10.1</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>Biosynthesis and metabolism of androgens and target genes for prostate cancer prevention and treatment. Genes involved in the androgen pathway are in bold. They are discussed in the text. <Emphasis Type="Italic">AR</Emphasis> androgen receptor, <Emphasis Type="Italic">CYP</Emphasis> cythocrome P450, <Emphasis Type="Italic">DHEA</Emphasis> dehydroepiandrosterone, <Emphasis Type="Italic">DHT</Emphasis> dihydrotestosterone, <Emphasis Type="Italic">HSD</Emphasis> hydroxysteroid dehydrogenase, <Emphasis Type="Italic">MES</Emphasis> methylseleninic acid, <Emphasis Type="Italic">SARM</Emphasis> selective AR modulators, <Emphasis Type="Italic">SLCO1B3</Emphasis> solute carrier organic anion transporter family member 1B3, <Emphasis Type="Italic">SRD5A</Emphasis> steroid 5α-reductase (type I, II, or III), <Emphasis Type="Italic">VES</Emphasis> α-tocopheryl succinate (vitamin E)</SimplePara>
                  </CaptionContent>
                </Caption>
                <MediaObject ID="MO1_10">
                  <ImageObject Color="Color" FileRef="MediaObjects/978-1-60327-829-4_10_Fig1_HTML.gif" Format="GIF" Rendition="HTML" Type="Linedraw"/>
                </MediaObject>
              </Figure>
            </Para>
            <Para TextBreak="No">Prostate cancer (CaP) is the most common cancer diagnosis in males and is highly prevalent in many countries [<CitationRef CitationID="CR4_10">4</CitationRef>, <CitationRef CitationID="CR5_10">5</CitationRef>]. Androgens are very important to CaP development and progression. It was observed that the prostate atrophies with withdrawal of androgenic hormones, and eunuchoid individuals do not develop the disease [<CitationRef CitationID="CR6_10">6</CitationRef>]. In an animal model, early castration testified to significantly reduce prostate tumor growth [<CitationRef CitationID="CR7_10">7</CitationRef>]. Also an in vitro model showed that there is a molecular mechanism of androgen action in cell cycle regulation and growth in prostate carcinoma [<CitationRef CitationID="CR8_10">8</CitationRef>]. Moreover, androgen deprivation therapy (ADT) is the most common and efficient therapy currently in use for metastic CaP (for review, see [<CitationRef CitationID="CR9_10">9</CitationRef>]).</Para>
            <Para TextBreak="No">In this chapter, we will review significant polymorphisms, especially single nucleotide polymorphisms (SNPs), found in various androgen metabolic genes, and we will evaluate their contribution to CaP chemoprevention and treatment.</Para>
          </Section1>
          <Section1 ID="Sec2">
            <Heading>Prostate Cancer and Androgen Therapy and Prevention</Heading>
            <Section2 ID="Sec3">
              <Heading>Treatment of Prostate Cancer</Heading>
              <Para TextBreak="No">Several different treatments for metastatic CaP are currently available, such as androgen ablation therapy, estrogen therapy, and steroidal and nonsteroidal antiandrogens (for review, see [<CitationRef CitationID="CR10_10">10</CitationRef>]). We will review here those that are involved in the androgen metabolism and are already in use therapeutically in CaP patients.</Para>
              <Para TextBreak="No">Since the early 1940s, ADT has been the main treatment for metastatic CaP, first reported with the removal of the prostate [<CitationRef CitationID="CR11_10">11</CitationRef>]. Nowadays, chemical treatment is the most popular choice, with the use of gonadotropin-releasing hormone (GnRH) agonists (for review, see [<CitationRef CitationID="CR9_10">9</CitationRef>]). Other medications called antiandrogens, such as flutamide, bicalutamide, nilutamide (nonsteroidal antiandrogens), and cyproterone acetate (steroidal antiandrogens), block the action of androgens within CaP cells [<CitationRef CitationID="CR10_10">10</CitationRef>] (see Fig. <InternalRef RefID="Fig1">10.1</InternalRef>). They inhibit the binding of testosterone and DHT to specific receptors in tumor cells.</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec4">
            <Heading>Prevention of Prostate Cancer</Heading>
            <Para TextBreak="No">Diverse substances have been studied as potential chemopreventives for CaP. Here, we will review only the ones that are in phase III trials or for which trials have been concluded and shown substantial effects. For more information about prevention of CaP, see <ExternalRef>
                <RefSource>Chap. 31</RefSource>
                <RefTarget Address="10.1007/978-1-60327-829-4_31" TargetType="DOI"/>
              </ExternalRef> of this book.</Para>
            <Para TextBreak="No">Finasteride is a potent SRD5A type II inhibitor [<CitationRef CitationID="CR12_10">12</CitationRef>, <CitationRef CitationID="CR13_10">13</CitationRef>] utilized in the prevention of prostate cancer. A large 7-year study called the Prostate Cancer Prevention Trial (PCPT) showed that men who had regular doses of finasteride had a decreased risk of CaP by 24.8% [<CitationRef CitationID="CR14_10">14</CitationRef>]. It was observed, however, that the same group had a higher incidence of high-grade CaP compared with placebo [<CitationRef CitationID="CR14_10">14</CitationRef>]. Interestingly and importantly, this original finding has recently become controversial [<CitationRef CitationID="CR15_10">15</CitationRef>, <CitationRef CitationID="CR16_10">16</CitationRef>]. Finasteride, in the meantime, seems to facilitate the detection of CaP and to inhibit low-grade cancers instead of increasing their rates [<CitationRef CitationID="CR15_10">15</CitationRef>, <CitationRef CitationID="CR16_10">16</CitationRef>]. Avoiding DHT synthesis through SRD5A2 inhibition could be a useful strategy to delay or prevent the initiation of CaP. Until now, finasteride is the only agent proven to be efficient in the reduction of prostate carcinoma in a randomized and placebo-controlled phase III study [<CitationRef CitationID="CR17_10">17</CitationRef>].</Para>
            <Para TextBreak="No">Dutasteride is another SRD5A inhibitor, and it acts on both type I and type II enzymes [<CitationRef CitationID="CR18_10">18</CitationRef>, <CitationRef CitationID="CR19_10">19</CitationRef>]. It is antiandrogenic and promotes cell death in CaP cells [<CitationRef CitationID="CR20_10">20</CitationRef>, <CitationRef CitationID="CR21_10">21</CitationRef>]. The results of a 4-year study called Reduction by Dutasteride of Prostate Cancer Events (REDUCE), a phase III trial, were disclosed in 2008 [<CitationRef CitationID="CR22_10">22</CitationRef>].</Para>
            <Para TextBreak="No">Methylseleninic acid (MSA) seems to modulate the expression of diverse androgen-regulated genes and suppress AR and prostate-specific antigen (PSA) expressions [<CitationRef CitationID="CR23_10">23</CitationRef>, <CitationRef CitationID="CR24_10">24</CitationRef>] and inhibit the growth of CaP in vivo [<CitationRef CitationID="CR24_10">24</CitationRef>]. In the same way, a stereoisomer of vitamin E, α-tocopheryl succinate (VES), has shown to suppress AR expression [<CitationRef CitationID="CR25_10">25</CitationRef>]. The Selenium and vitamin E Cancer Prevention Trial (SELECT) examines MSA and VES [<CitationRef CitationID="CR26_10">26</CitationRef>] in relation to CaP prevention. The results of the SELECT trial are discussed in Chap. 31.</Para>
          </Section1>
          <Section1 ID="Sec5">
            <Heading>Genes and Polymorphisms in the Androgen Pathway in Prostate Cancer</Heading>
            <Para TextBreak="No">Diverse genes involved in the androgen pathway (see Fig. <InternalRef RefID="Fig1">10.1</InternalRef>) have been analyzed in relation to the risk of CaP. Here we will evaluate the ones relevant to the pharmacogenetics analysis.</Para>
          </Section1>
          <Section1 ID="Sec6">
            <Heading>Androgen Receptor</Heading>
            <Para TextBreak="No">The <Emphasis Type="Italic">AR</Emphasis> gene (located in Xq11.2-q12) is a steroid-binding transcription factor that regulates prostate cellular proliferation and differentiation [<CitationRef CitationID="CR27_10">27</CitationRef>] (Table <InternalRef RefID="Tab1">10.1</InternalRef>). It is the main gene studied in CaP risk as it is involved in the regulation of diverse genes of cell regulation and binds to both DHT and testosterone. The AR gene comprises eight exons that encode four functional domains. The amino-terminal transactivation domain (exon 1), which is the transcriptional regulatory region of the protein and regulates the expression of target genes, is highly polymorphic. The DNA-binding domain is coded by exons 2 and 3, while exons 4–8 code to a hinge region and a carboxyl-terminal ligand-binding domain [<CitationRef CitationID="CR27_10">27</CitationRef>]. The transactivation domain, which regulates the expression of target genes and represents 60% of the entire protein, is highly polymorphic [<CitationRef CitationID="CR28_10">28</CitationRef>]. Irrespective of how current CaP treatments affect the levels of circulating androgens, the most important factor determining the success or failure of the treatment is the AR protein [<CitationRef CitationID="CR29_10">29</CitationRef>]. Moreover, the development of selective AR modulators (SARM), such as pyrazolines, is also promising as a CaP treatment [<CitationRef CitationID="CR29_10">29</CitationRef>]. Consequently, a complete understanding of the AR is necessary in the search for new approaches in the prevention and treatment of prostate cancer [<CitationRef CitationID="CR29_10">29</CitationRef>]. It was shown by immunohistochemistry of CaP tissues that AR is upregulated in high-grade or advanced disease [<CitationRef CitationID="CR30_10">30</CitationRef>].<Table Float="Yes" ID="Tab1">
                <Caption Language="En">
                  <CaptionNumber>Table 10.1</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>Variants of the androgen receptor gene, reported functional effects and association studies with prostate cancer</SimplePara>
                  </CaptionContent>
                </Caption>
                <tgroup cols="3">
                  <colspec colname="c1" colnum="1"/>
                  <colspec colname="c2" colnum="2"/>
                  <colspec colname="c3" colnum="3"/>
                  <thead>
                    <row>
                      <entry colname="c1">
                        <SimplePara>AR variant</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Reported functional effects</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Association studies</SimplePara>
                      </entry>
                    </row>
                  </thead>
                  <tbody>
                    <row>
                      <entry colname="c1">
                        <SimplePara>(CAG)<Subscript>
                            <Emphasis Type="Italic">n</Emphasis>
                          </Subscript>
                        </SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Structurally altered protein with reduced transcriptional activity [<CitationRef CitationID="CR31_10">31</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Positive but small association with short repeats in meta-analysis [<CitationRef CitationID="CR32_10">32</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>(GGN)<Subscript>
                            <Emphasis Type="Italic">n</Emphasis>
                          </Subscript>
                        </SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Structurally altered protein [<CitationRef CitationID="CR31_10">31</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Positive but small association with short repeats in meta-analysis [<CitationRef CitationID="CR32_10">32</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>E211E</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>None</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Contradictory [<CitationRef CitationID="CR38_10">38</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Q640Stop</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>C-terminal truncated AR [<CitationRef CitationID="CR31_10">31</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Associated with low risk of metastatic CaP [<CitationRef CitationID="CR96_10">96</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>L701H</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Reduced affinity to DHT but increased to glucocorticoids [<CitationRef CitationID="CR23_10">23</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>None</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>R726L</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Change transactivational specificity of the AR [<CitationRef CitationID="CR31_10">31</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Contradictory [<CitationRef CitationID="CR38_10">38</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>A748T</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Decreased stability [<CitationRef CitationID="CR31_10">31</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>None</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>T877A</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Enlarged ligand specificity [<CitationRef CitationID="CR31_10">31</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>None</SimplePara>
                      </entry>
                    </row>
                  </tbody>
                </tgroup>
                <tfooter>
                  <SimplePara>
                    <Emphasis Type="Italic">AR</Emphasis> androgen receptor, <Emphasis Type="Italic">DHT</Emphasis> dyhydrotestosterone, <Emphasis Type="Italic">CaP</Emphasis> prostate cancer</SimplePara>
                </tfooter>
              </Table>
            </Para>
            <Para TextBreak="No">More than 600 somatic mutations have been reported for the <Emphasis Type="Italic">AR</Emphasis> gene; of those, about 85, most of them in advanced grades, have been described in CaP (for review, see [<CitationRef CitationID="CR29_10">29</CitationRef>]). Many of these mutations could change the affinity for ligands and increase transcriptional activity [<CitationRef CitationID="CR29_10">29</CitationRef>]. The most noteworthy polymorphisms are a (CAG)<Subscript>
                <Emphasis Type="Italic">n</Emphasis>
              </Subscript> (coding for polyglutamine) and a (GGN)<Subscript>
                <Emphasis Type="Italic">n</Emphasis>
              </Subscript> (coding for glycine) triplet repeats in exon 1 (see Table <InternalRef RefID="Tab1">10.1</InternalRef>). Both are expected to produce structurally altered proteins (for review, see [<CitationRef CitationID="CR31_10">31</CitationRef>]). A meta-analysis showed that shorter repeats of both polymorphisms may increase the risk of CaP, although these increased risks appear to be very small [<CitationRef CitationID="CR32_10">32</CitationRef>]. More recent investigations about the role of these trinucleotides in CaP predisposition are also contradictory (for review, see [<CitationRef CitationID="CR33_10">33</CitationRef>]). Perhaps they could be in linkage disequilibrium (LD) with other important regions of the gene [<CitationRef CitationID="CR32_10">32</CitationRef>]. Although diverse polymorphisms have been analyzed in this gene in relation to CaP risk (see Table <InternalRef RefID="Tab1">10.1</InternalRef>), none of them have conclusive results, mostly because of the difference between ethnicities. Meta-analysis and larger studies regarding population stratification should help to elucidate the role of the AR gene in prostate carcinoma development and progression. Most of them have functional effects in the protein and may be involved in an altered response to treatment. Detailed analysis about the biology of the AR in CaP is discussed in <ExternalRef>
                <RefSource>Chap. 5</RefSource>
                <RefTarget Address="10.1007/978-1-60327-829-4_5" TargetType="DOI"/>
              </ExternalRef> of this book.</Para>
          </Section1>
          <Section1 ID="Sec7">
            <Heading>The Steroid 5α-Reductase Family</Heading>
            <Para TextBreak="No">The three SRD5A isozymes are apparently expressed in different tissues. Type I is mostly expressed in nonreproductive tissues including skin and liver [<CitationRef CitationID="CR34_10">34</CitationRef>, <CitationRef CitationID="CR35_10">35</CitationRef>] and type II predominantly in the male reproductive tissues such as seminal vesicles, epididymis, and prostate [<CitationRef CitationID="CR34_10">34</CitationRef>, <CitationRef CitationID="CR35_10">35</CitationRef>]. The type III (or 2L) enzyme, which was described more recently, seems to work like type I [<CitationRef CitationID="CR36_10">36</CitationRef>]. Diverse studies have shown that SRD5A1 expression is increased in cancer tissue [<CitationRef CitationID="CR36_10">36</CitationRef>–<CitationRef CitationID="CR39_10">39</CitationRef>], while expression and activity are decreased for SRD5A2 [<CitationRef CitationID="CR36_10">36</CitationRef>, <CitationRef CitationID="CR37_10">37</CitationRef>, <CitationRef CitationID="CR40_10">40</CitationRef>–<CitationRef CitationID="CR42_10">42</CitationRef>]. A study of immunostaining in CaP tissue of nontreated patients reported that both enzymes were increased in high versus low-grade tumors [<CitationRef CitationID="CR38_10">38</CitationRef>]. These results suggest that SRD5A1 might be more important in CaP progression and development than originally thought. Like the other genes of the family, SRD5A3 might produce DHT, and its expression seems to be increased in CaP [<CitationRef CitationID="CR36_10">36</CitationRef>].</Para>
            <Para TextBreak="No">Several polymorphisms in the <Emphasis Type="Italic">SRD5A2</Emphasis> gene (located in band 2p23) have been extensively studied in terms of CaP risk (for review, see [<CitationRef CitationID="CR33_10">33</CitationRef>]) (Table <InternalRef RefID="Tab2">10.2</InternalRef>). The most commonly analyzed polymorphism is a nonsynonymous SNP in exon 1, A49T, an alanine to threonine substitution (first reported by [<CitationRef CitationID="CR43_10">43</CitationRef>] in the Hawaii–Los-Angeles Multiethnic Cohort – MEC), which is believed to increase the levels of enzyme activity about fivefold [<CitationRef CitationID="CR44_10">44</CitationRef>]. Diverse studies have evaluated this polymorphism in relation to CaP, and the results are contradictory (for review, see [<CitationRef CitationID="CR45_10">45</CitationRef>]). However, the updated analysis of a larger MEC sample (6,000 controls vs. 6,000 patients) did not show any positive association between A49T and CaP risk in four ethnic groups [<CitationRef CitationID="CR46_10">46</CitationRef>]. Different genotyping techniques were utilized, and that apparently explains the discrepancy between these and previous results [<CitationRef CitationID="CR46_10">46</CitationRef>]. Moreover, meta-analyses support very small association and little effect of this polymorphism with CaP [<CitationRef CitationID="CR45_10">45</CitationRef>, <CitationRef CitationID="CR46_10">46</CitationRef>]. The low frequency of the polymorphic T allele (1%) also implies that the public health impact would be low [<CitationRef CitationID="CR46_10">46</CitationRef>]. This case highlights the importance of experimental replications and very large samples in association studies in multifactorial diseases and the severe control quality of the results.<Table Float="Yes" ID="Tab2">
                <Caption Language="En">
                  <CaptionNumber>Table 10.2</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>Variants of the steroid 5α-hydroxylase (<Emphasis Type="Italic">SRD5A2</Emphasis>) gene, reported functional effects, association study and pharmacogenetic variation with prostate cancer risk</SimplePara>
                  </CaptionContent>
                </Caption>
                <tgroup cols="5">
                  <colspec colname="c1" colnum="1"/>
                  <colspec colname="c2" colnum="2"/>
                  <colspec colname="c3" colnum="3"/>
                  <colspec colname="c4" colnum="4"/>
                  <colspec colname="c5" colnum="5"/>
                  <thead>
                    <row>
                      <entry colname="c1">
                        <SimplePara>SRD5A2 variants</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Somatic or constitutional DNA</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Reported functional effects</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Association studies</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Pharmacogenetic variation<Superscript>a</Superscript>
                        </SimplePara>
                      </entry>
                    </row>
                  </thead>
                  <tbody>
                    <row>
                      <entry colname="c1">
                        <SimplePara>V3I in exon 1 [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Somatic [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Increased enzyme activity [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>None</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Increased sensitivity to finasteride, decreased sensitivity to dutasteride [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>C5R in exon 1 [<CitationRef CitationID="CR44_10">44</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Constitutional [<CitationRef CitationID="CR44_10">44</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Almost the same [<CitationRef CitationID="CR44_10">44</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>None</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Almost same sensitivity to finasteride and dutasteride 1,3</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>P30L in exon 1 [<CitationRef CitationID="CR44_10">44</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Constitutional [<CitationRef CitationID="CR44_10">44</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Decreased enzyme activity [<CitationRef CitationID="CR44_10">44</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>None</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Decreased sensitivity to finasteride 1,3</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>P48R in exon 1 [<CitationRef CitationID="CR44_10">44</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Constitutional [<CitationRef CitationID="CR44_10">44</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Decreased enzyme activity [<CitationRef CitationID="CR44_10">44</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>None</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Increased sensitivity to finasteride [<CitationRef CitationID="CR44_10">44</CitationRef>, <CitationRef CitationID="CR87_10">87</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>A49T in exon 1 [<CitationRef CitationID="CR44_10">44</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Constitutional [<CitationRef CitationID="CR87_10">87</CitationRef>] and somatic [<CitationRef CitationID="CR44_10">44</CitationRef>, <CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Increased enzyme activity [<CitationRef CitationID="CR44_10">44</CitationRef>, <CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Negative meta-analyses [<CitationRef CitationID="CR45_10">45</CitationRef>, <CitationRef CitationID="CR46_10">46</CitationRef>] and large sample [<CitationRef CitationID="CR46_10">46</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Decreased sensitivity to finasteride, increased sensitivity to dutasteride [<CitationRef CitationID="CR44_10">44</CitationRef>, <CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>A51T in exon 1 [<CitationRef CitationID="CR44_10">44</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Constitutional [<CitationRef CitationID="CR44_10">44</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Slightly decreased in activity [<CitationRef CitationID="CR44_10">44</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>None</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Slightly increased sensitivity to finasteride, slightly decreased sensitivity to dutasteride [<CitationRef CitationID="CR44_10">44</CitationRef>, <CitationRef CitationID="CR87_10">87</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>V63M in exon 1 [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Somatic [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Slightly decreased in activity [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>None</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Increased sensitivity to finasteride, decreased sensitivity to dutasteride [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>V89L in exon 14</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Constitutional [<CitationRef CitationID="CR44_10">44</CitationRef>, <CitationRef CitationID="CR47_10">47</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Decreased enzyme activity [<CitationRef CitationID="CR44_10">44</CitationRef>, <CitationRef CitationID="CR47_10">47</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Negative meta-analysis [<CitationRef CitationID="CR45_10">45</CitationRef>], LL associated with CaP in large sample [<CitationRef CitationID="CR49_10">49</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Decreased sensitivity to finasteride, increased sensitivity to dutasteride [<CitationRef CitationID="CR44_10">44</CitationRef>, <CitationRef CitationID="CR87_10">87</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>F118L in exon 2 [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Somatic [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Increased enzyme activity [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>None</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Increased sensitivity to finasteride and dutasteride [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>G183D in exon 4 [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Somatic [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Slightly decreased in activity [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>None</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Increased sensitivity to finasteride [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>T187M in exon 4 [<CitationRef CitationID="CR44_10">44</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Constitutional [<CitationRef CitationID="CR44_10">44</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Decreased enzyme activity [<CitationRef CitationID="CR44_10">44</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>None</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Slightly decreased for both finasteride and dutasteride [<CitationRef CitationID="CR44_10">44</CitationRef>, <CitationRef CitationID="CR87_10">87</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>V189L in exon 4 [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Somatic [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Decreased enzyme activity [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>None</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Decreased sensitivity to finasteride, slightly decreased to dutasteride [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>G191E in exon 4 [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Somatic [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Decreased enzyme activity [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>None</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Increased sensitivity to finasteride, slightly decreased to dutasteride [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>F194L in exon 4 [<CitationRef CitationID="CR44_10">44</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Constitutional [<CitationRef CitationID="CR44_10">44</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Increased enzyme activity [<CitationRef CitationID="CR44_10">44</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>None</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Increased sensitivity to finasteride [<CitationRef CitationID="CR44_10">44</CitationRef>, <CitationRef CitationID="CR87_10">87</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>L221P in exon 4 [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Somatic [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Decreased enzyme activity [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>None</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Almost same sensitivity to finasteride, slightly increased to dutasteride [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>L226P in exon 4 [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Somatic [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Slightly decreased in activity [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>None</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Decreased sensitivity to finasteride, increased sensitivity to dutasteride [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>R227Q in exon 4 [<CitationRef CitationID="CR44_10">44</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Constitutional [<CitationRef CitationID="CR44_10">44</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Decreased enzyme activity [<CitationRef CitationID="CR44_10">44</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Negative [<CitationRef CitationID="CR97_10">97</CitationRef>, <CitationRef CitationID="CR98_10">98</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Decreased sensitivity to finasteride, increased sensitivity to dutasteride [<CitationRef CitationID="CR44_10">44</CitationRef>, <CitationRef CitationID="CR87_10">87</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>F234L in exon 4 [<CitationRef CitationID="CR44_10">44</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Constitutional [<CitationRef CitationID="CR44_10">44</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Decreased enzyme activity [<CitationRef CitationID="CR44_10">44</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>None</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Decreased sensitivity to finasteride, increased sensitivity to dutasteride [<CitationRef CitationID="CR44_10">44</CitationRef>, <CitationRef CitationID="CR87_10">87</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>A248V in exon 5 [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Somatic [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Increased enzyme activity [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>None</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Decreased sensitivity to finasteride, increased sensitivity to dutasteride [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>(TA)<Subscript>
                            <Emphasis Type="Italic">n</Emphasis>
                          </Subscript> in 5’UTR</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Constitutional [<CitationRef CitationID="CR48_10">48</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>None</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Negative meta-analysis [<CitationRef CitationID="CR45_10">45</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>None</SimplePara>
                      </entry>
                    </row>
                  </tbody>
                </tgroup>
                <tfooter>
                  <SimplePara>
                    <Superscript>a</Superscript>The pharmacogenetic variation was compared to wild type</SimplePara>
                </tfooter>
              </Table>
            </Para>
            <Para TextBreak="No">Other polymorphisms in <Emphasis Type="Italic">SRD5A2</Emphasis> gene have been evaluated (see Table <InternalRef RefID="Tab2">10.2</InternalRef>), such as the missense SNP V89L (a valine to leucine substitution), which reduces SRD5A2 activity in vitro [<CitationRef CitationID="CR47_10">47</CitationRef>] and a (TA)<Subscript>
                <Emphasis Type="Italic">n</Emphasis>
              </Subscript> dinucleotide repeat located in the 3′ untranslated region after exon 5 [<CitationRef CitationID="CR48_10">48</CitationRef>]. Both, however, were not associated with CaP in meta-analyses [<CitationRef CitationID="CR45_10">45</CitationRef>]. Nevertheless, more recently an investigation evaluated 803 CaP cases and 802 controls in relation to the V89L SNP and found that the L/L genotype was associated with increased risk of the disease and also higher aggressiveness [<CitationRef CitationID="CR49_10">49</CitationRef>]. The association with the low-activity variant corroborates with the PCPT findings with long-term exposition of finasteride and inhibition of SRD5A2 [<CitationRef CitationID="CR49_10">49</CitationRef>]. SRD5A1 (5p15) and SRD5A3 (4q12) polymorphisms have not been studied until now in relation to prostate carcinoma. Probably in the future, more researchers will approach these genes, as their role in CaP development and progression is emerging.</Para>
          </Section1>
          <Section1 ID="Sec8">
            <Heading>Aromatase (CYP19A1)</Heading>
            <Para TextBreak="No">The aromatase enzyme, encoded by <Emphasis Type="Italic">CYP19A1</Emphasis> gene (15q21.1), is a critical regulator of the balance between androgens and estrogens and contributes to circulating and tissue levels of these hormones in the prostate (see Fig. <InternalRef RefID="Fig1">10.1</InternalRef>). Aromatase inhibitors work to block the production of estradiol, widely used in breast cancer treatment, they are another possibility for CaP treatment (for review, see [<CitationRef CitationID="CR50_10">50</CitationRef>]), which suggests that intraprostatic estradiol might contribute to the disease [<CitationRef CitationID="CR51_10">51</CitationRef>]. However, phase II trials using aromatase inhibitors, such as anastrozole and tetrozole, did not present satisfactory results as a CaP treatment [<CitationRef CitationID="CR52_10">52</CitationRef>, <CitationRef CitationID="CR53_10">53</CitationRef>].</Para>
            <Para TextBreak="No">The analyses of mRNA in various tissues showed that aromatase transcripts are tissue-specifically regulated, with differential splice patterns in the prostate [<CitationRef CitationID="CR54_10">54</CitationRef>]. The results of expression of this enzyme in benign or carcinogen prostate are unfortunately contradictory [<CitationRef CitationID="CR51_10">51</CitationRef>, <CitationRef CitationID="CR55_10">55</CitationRef>, <CitationRef CitationID="CR56_10">56</CitationRef>]. Few studies have evaluated polymorphisms in this gene and their relation to CaP risk (Table <InternalRef RefID="Tab3">10.3</InternalRef>). More than seven repeats of a tetranucleotide repeat (TTTA)<Subscript>
                <Emphasis Type="Italic">n</Emphasis>
              </Subscript> in intron 4 were associated with decreased survival in men with metastatic CaP [<CitationRef CitationID="CR57_10">57</CitationRef>]. The repeat alleles of 171 and 187 bp in size were associated with CaP patients in another study as well [<CitationRef CitationID="CR58_10">58</CitationRef>]. However, other studies were not able to observe any association between this tetranucleotide repeat and CaP risk [<CitationRef CitationID="CR59_10">59</CitationRef>, <CitationRef CitationID="CR60_10">60</CitationRef>]. Another polymorphism analyzed was the SNP R264C (a C to T substitution in exon 7), with positive reports [<CitationRef CitationID="CR61_10">61</CitationRef>, <CitationRef CitationID="CR62_10">62</CitationRef>], which yielded negative results as well [<CitationRef CitationID="CR59_10">59</CitationRef>, <CitationRef CitationID="CR63_10">63</CitationRef>].<Table Float="Yes" ID="Tab3">
                <Caption Language="En">
                  <CaptionNumber>Table 10.3</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>Genes in the androgen pathway involved in prostate cancer development and progression</SimplePara>
                  </CaptionContent>
                </Caption>
                <tgroup cols="5">
                  <colspec colname="c1" colnum="1"/>
                  <colspec colname="c2" colnum="2"/>
                  <colspec colname="c3" colnum="3"/>
                  <colspec colname="c4" colnum="4"/>
                  <colspec colname="c5" colnum="5"/>
                  <thead>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Gene name</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Polymorphism studied</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Expression in CaP</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Association to CaP risk</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Relevance to pharmacogenetic</SimplePara>
                      </entry>
                    </row>
                  </thead>
                  <tbody>
                    <row>
                      <entry colname="c1">
                        <SimplePara>
                          <Emphasis Type="Italic">CYP17</Emphasis>
                        </SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>T for C in the 5′UTR (A2 allele)</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Inconclusive results for the gene expression in CaP<Superscript>a</Superscript>
                        </SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Negative meta-analysis [<CitationRef CitationID="CR65_10">65</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>None</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1" morerows="2">
                        <SimplePara>
                          <Emphasis Type="Italic">CYP19A1</Emphasis>
                        </SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>A/C SNP 5 kb upstream the gene (rs1870050)</SimplePara>
                      </entry>
                      <entry colname="c3" morerows="2">
                        <SimplePara>Inconclusive results for aromatase expression in CaP<Superscript>a</Superscript>
                        </SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>None</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>rs1870050 was associated with TTP during ADT [<CitationRef CitationID="CR94_10">94</CitationRef>]<Superscript>a</Superscript>
                        </SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c2">
                        <SimplePara>(TTTA)<Subscript>
                            <Emphasis Type="Italic">n</Emphasis>
                          </Subscript> repeat in intron 4</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Inconclusive<Superscript>a</Superscript>
                        </SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Aromatase inhibitors were unsuccessful used as a CaP treatment<Superscript>a</Superscript>
                        </SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c2">
                        <SimplePara>R264C in exon 7 (C/T)</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Inconclusive<Superscript>a</Superscript>
                        </SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>None</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1" morerows="1">
                        <SimplePara>
                          <Emphasis Type="Italic">HSD3B1</Emphasis>
                        </SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>L338L (C/T) in exon 3</SimplePara>
                      </entry>
                      <entry colname="c3" morerows="1">
                        <SimplePara>None</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Both SNPs associated with tumor aggressiveness [<CitationRef CitationID="CR59_10">59</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Associated with TTP during ADT [<CitationRef CitationID="CR94_10">94</CitationRef>]<Superscript>a</Superscript>
                        </SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c2">
                        <SimplePara>N367T (A/C) in exon 4</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Weak association with CaP risk [<CitationRef CitationID="CR74_10">74</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>None</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1" morerows="1">
                        <SimplePara>
                          <Emphasis Type="Italic">HSB3B2</Emphasis>
                        </SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>(TG)<Subscript>
                            <Emphasis Type="Italic">n</Emphasis>
                          </Subscript> (TA)<Subscript>
                            <Emphasis Type="Italic">n</Emphasis>
                          </Subscript> (CA)<Subscript>
                            <Emphasis Type="Italic">n</Emphasis>
                          </Subscript> repeat in exon 3</SimplePara>
                      </entry>
                      <entry colname="c3" morerows="1">
                        <SimplePara>Gene is overexpressed in androgen-independent CaP [<CitationRef CitationID="CR72_10">72</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Inconclusive<Superscript>a</Superscript>
                        </SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>None</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c2">
                        <SimplePara>C7519G in the 3′UTR</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Effect in association with L338L of <Emphasis Type="Italic">HSD3B1</Emphasis> [<CitationRef CitationID="CR74_10">74</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>None</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>
                          <Emphasis Type="Italic">HSD17B1</Emphasis>
                        </SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>26 Polymorphisms studied</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>None</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Negative large study [<CitationRef CitationID="CR75_10">75</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Overexpression in dutasteride-treated cells [<CitationRef CitationID="CR89_10">89</CitationRef>]<Superscript>a</Superscript>
                        </SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>
                          <Emphasis Type="Italic">HSD17B3</Emphasis>
                        </SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>G289S (G/A) in exon 11</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Gene is overexpressed in high-grade CaP [<CitationRef CitationID="CR76_10">76</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>Associated with increase risk in Caucasians [<CitationRef CitationID="CR99_10">99</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Overexpression in dutasteride-treated cells [<CitationRef CitationID="CR89_10">89</CitationRef>]<Superscript>a</Superscript>
                        </SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>
                          <Emphasis Type="Italic">HSD17B4</Emphasis>
                        </SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>Intronic SNP (C/G) (rs7737181)</SimplePara>
                      </entry>
                      <entry colname="c3">
                        <SimplePara>Gene is overexpressed in high-grade CaP [<CitationRef CitationID="CR76_10">76</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c4">
                        <SimplePara>None</SimplePara>
                      </entry>
                      <entry colname="c5">
                        <SimplePara>Associated with TTP during ADT [<CitationRef CitationID="CR94_10">94</CitationRef>]<Superscript>a</Superscript>
                        </SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1" morerows="1">
                        <SimplePara>
                          <Emphasis Type="Italic">SLCO1B3</Emphasis>
                        </SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>S112A (T/G) in exon 3</SimplePara>
                      </entry>
                      <entry colname="c3" morerows="1">
                        <SimplePara>Gene is overexpressed in CaP and it is dependent of the genotype; variants are less active than wild type [<CitationRef CitationID="CR79_10">79</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c4" morerows="1">
                        <SimplePara>Both polymorphisms are in LD; haplotype of homozygous to variants is associated with better survival of CaP patients [<CitationRef CitationID="CR79_10">79</CitationRef>]</SimplePara>
                      </entry>
                      <entry colname="c5" morerows="1">
                        <SimplePara>Presence of T (wild type) associated with shorter time to androgen independence [<CitationRef CitationID="CR95_10">95</CitationRef>]<Superscript>a</Superscript>
                        </SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c2">
                        <SimplePara>M233I (G/A) in exon 6</SimplePara>
                      </entry>
                    </row>
                  </tbody>
                </tgroup>
                <tfooter>
                  <SimplePara>
                    <Emphasis Type="Italic">CaP</Emphasis> prostate cancer, <Emphasis Type="Italic">LD</Emphasis> linkage disequilibrium, <Emphasis Type="Italic">TTP</Emphasis> time to progression, <Emphasis Type="Italic">ADT</Emphasis> androgen deprivation therapy</SimplePara>
                  <SimplePara>
                    <Superscript>a</Superscript>See text for more details</SimplePara>
                </tfooter>
              </Table>
            </Para>
          </Section1>
          <Section1 ID="Sec9">
            <Heading>Other Genes</Heading>
            <Para TextBreak="No">Various genes have been approached in the androgen metabolism in relation to CaP risk [<CitationRef CitationID="CR33_10">33</CitationRef>]. However, their role in the disease is not as well comprehended as the other genes discussed above. These genes have been rapidly reviewed in this section (see Table <InternalRef RefID="Tab3">10.3</InternalRef>).</Para>
            <Para TextBreak="No">The cytochrome P450 17 (<Emphasis Type="Italic">CYP17</Emphasis>) gene (10q24.3) encodes for the enzyme P450c 17α-hydroxylase (see Fig. <InternalRef RefID="Fig1">10.1</InternalRef>). The 5′ untranslated promoter region of the gene contains a substitution of T for a C (A1 and A2 alleles) [<CitationRef CitationID="CR64_10">64</CitationRef>]. Although diverse studies were done and the results were often conflicting, a meta-analysis of 12 case-control studies suggests that the C/C genotype is unlikely to be a major risk factor for sporadic CaP on a wide population base, especially in men of European descent (see Table <InternalRef RefID="Tab3">10.3</InternalRef>) [<CitationRef CitationID="CR65_10">65</CitationRef>]. This result is supported by recent analyses in large samples [<CitationRef CitationID="CR60_10">60</CitationRef>, <CitationRef CitationID="CR66_10">66</CitationRef>, <CitationRef CitationID="CR67_10">67</CitationRef>]. There is a controversy on whether this polymorphism would increase the expression levels of the gene, creating an additional Sp1-binding site in the promoter [<CitationRef CitationID="CR64_10">64</CitationRef>, <CitationRef CitationID="CR68_10">68</CitationRef>]. Moreover, the levels of serum hormone in men seemed not to correlate with the genotype of this polymorphism [<CitationRef CitationID="CR66_10">66</CitationRef>, <CitationRef CitationID="CR67_10">67</CitationRef>, <CitationRef CitationID="CR69_10">69</CitationRef>]. However, Sp1, Sp3, and NF-1C binding sites are essential transcriptional factors for the expression of CYP17 gene [<CitationRef CitationID="CR70_10">70</CitationRef>].</Para>
            <Para TextBreak="No">The enzyme 3β-hydroxysteroid dehydrogenase (HSD3B) is responsible for the inactivation of DHT in steroid target tissues (see Fig. <InternalRef RefID="Fig1">10.1</InternalRef>). The <Emphasis Type="Italic">HSD3B</Emphasis> gene family is composed of two genes and five pseudogenes, which are all located in chromosome band 1p13.1. The type I and type II enzymes are differentially expressed [<CitationRef CitationID="CR71_10">71</CitationRef>]. HSD3B2 expression was observed to be increased in androgen-independent CaP [<CitationRef CitationID="CR72_10">72</CitationRef>]. This would increase androstenedione levels, which could generate substrate for conversion into testosterone [<CitationRef CitationID="CR72_10">72</CitationRef>]. Diverse polymorphisms in <Emphasis Type="Italic">HSD3B1</Emphasis> and <Emphasis Type="Italic">HSD3B2</Emphasis> genes have been described and evaluated in CaP (see Table <InternalRef RefID="Tab3">10.3</InternalRef>) [<CitationRef CitationID="CR73_10">73</CitationRef>, <CitationRef CitationID="CR74_10">74</CitationRef>], and help to explain the racial and ethnic variations in the risk [<CitationRef CitationID="CR73_10">73</CitationRef>]. However, there is a general lack of biochemical analysis for these genes and polymorphisms.</Para>
            <Para TextBreak="No">The <Emphasis Type="Italic">HSD17</Emphasis> gene family catalyzes the interconversions between 17β-hydroxysteroids and 17-ketosteroids (see Fig. <InternalRef RefID="Fig1">10.1</InternalRef>). Although polymorphisms in the <Emphasis Type="Italic">HSD17B1</Emphasis> gene (located in 17q12-q21), including S3131G, have been described as a predisposition factor to CaP [<CitationRef CitationID="CR59_10">59</CitationRef>], any polymorphism of the 26 analyzed could be associated with the disease in a very large ethnically mixed sample (8,301 CaP cases vs. 9,373 controls) (see Table <InternalRef RefID="Tab3">10.3</InternalRef>) [<CitationRef CitationID="CR75_10">75</CitationRef>]. Different analyses for ethnicity were done to make sure that the negative associations were not due to population stratification [<CitationRef CitationID="CR75_10">75</CitationRef>]. The <Emphasis Type="Italic">HSD17B3</Emphasis> gene (9q22) encodes the testicular (or type III) enzyme (see Fig. <InternalRef RefID="Fig1">10.1</InternalRef>). Polymorphisms in this gene (Table <InternalRef RefID="Tab3">10.3</InternalRef>) might increase the output of testosterone, which can directly or indirectly activate AR through DHT, by potentially increasing the predisposition to CaP. The expression of <Emphasis Type="Italic">HSD17B3</Emphasis> and <Emphasis Type="Italic">HSD17B4</Emphasis> (5q2) genes were increased in high-grade CaP microdissections from radical prostatectomy samples [<CitationRef CitationID="CR76_10">76</CitationRef>]. These results are consistent with the overexpression of HSD17B4 at both mRNA and protein levels accompanied by increased enzymatic activity reported earlier [<CitationRef CitationID="CR77_10">77</CitationRef>]. Nevertheless, there is a need for the study of polymorphisms and their biochemical effects on these genes to evaluate if they are associated with increased risk of CaP.</Para>
            <Para TextBreak="No">The organic anion transporter OATP1B3 involved in the uptake of steroid anions, such as estradiol-17β-glucuronide, DHEA-3-sulfate, estrone-3-sulfate [<CitationRef CitationID="CR78_10">78</CitationRef>], and testosterone [<CitationRef CitationID="CR79_10">79</CitationRef>], is encoded by the solute carrier organic anion transporter 1B3 (<Emphasis Type="Italic">SLCO1B3</Emphasis>) gene [<CitationRef CitationID="CR80_10">80</CitationRef>]. This enzyme is considered to be important for drug elimination and pharmacokinetics, which could contribute to interindividual variability in drug response [<CitationRef CitationID="CR78_10">78</CitationRef>]. Two major SNPs are described in different populations: S112A in exon 3 and M233I in exon 6, which are in complete LD [<CitationRef CitationID="CR81_10">81</CitationRef>]. SLCO1B3 is overexpressed in CaP [<CitationRef CitationID="CR79_10">79</CitationRef>] (see Table <InternalRef RefID="Tab3">10.3</InternalRef>). Testosterone transport by OATP1B3 appears to be dependent on its genotype, the haplotype for the homozygous to the variant of both SNPs being less active in comparison to the normal [<CitationRef CitationID="CR79_10">79</CitationRef>]. In preclinical data, the same haplotype is associated with better survival in CaP patients; however, no difference was observed in relation to Gleason score [<CitationRef CitationID="CR79_10">79</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec10">
            <Heading>Gene Fusions</Heading>
            <Para TextBreak="No">In the last few years, several gene rearrangements have been described in patients with CaP. First, an androgen-responsive gene called fused transcription factor gene (TMPRSS2) was described in prostate carcinomas with an overexpression of the erythroblast transformation specific (ETS) transcription factor ERG, which regulates other genes’ activity [<CitationRef CitationID="CR82_10">82</CitationRef>]. Following that, diverse studies have confirmed their high levels in CaP patients (for review, see [<CitationRef CitationID="CR83_10">83</CitationRef>]), and other gene fusions, not so common, were also described (for review, see [<CitationRef CitationID="CR84_10">84</CitationRef>]). One of the new genes involved was kallikrein 2 (KLK2) [<CitationRef CitationID="CR85_10">85</CitationRef>] which, like PSA (also known as KLK3), is an androgen-induction and prostate-specific expressed gene [<CitationRef CitationID="CR86_10">86</CitationRef>]. The prostate cancer gene fusions are generally characterized by 5′ genomic regulatory elements, most of them controlled by androgen and fused to members of transcription factors that contribute to the overexpression of oncogenic transcription factors [<CitationRef CitationID="CR83_10">83</CitationRef>]. Studies with larger samples will be useful to identify specific clinical subtypes and different types of personalized medicine. Perhaps in the near future, these gene fusions will be utilized as biomarkers and as therapeutic targets to prostate cancer therapy.</Para>
          </Section1>
          <Section1 ID="Sec11">
            <Heading>Pharmacogenetics of Prostate Cancer</Heading>
            <Para TextBreak="No">Pharmacogenetic variation of different 5α-reductase inhibitors has been analyzed in the <Emphasis Type="Italic">SRD5A2</Emphasis> gene [<CitationRef CitationID="CR44_10">44</CitationRef>, <CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]. In a first study, ten single and three double constitutional amino acid substitutions were identified and biochemically characterized [<CitationRef CitationID="CR44_10">44</CitationRef>] (see Table <InternalRef RefID="Tab2">10.2</InternalRef>). Substantial pharmacogenetic variation was observed for finasteride, dutasteride, and PNU-157706 when incubated with the enzyme variants, and it was most pronounced with finasteride, especially for the mutants P30L, A49T, V89L, R227Q, F234L, and V89L-F234L (increased activity), and for P48R and F194L (decreased activity) [<CitationRef CitationID="CR44_10">44</CitationRef>] (see Table <InternalRef RefID="Tab2">10.2</InternalRef>). Furthermore, SRD5A2 somatic mutations in human CaP tissue were identified [<CitationRef CitationID="CR44_10">44</CitationRef>] and characterized in relation to finasteride and dutasteride [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]. Dutasteride proved to be more efficient as an inhibitor in vitro than finasteride in most variants [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>]. However, the efficacy of both drugs was dependent on the genotype of SRD5A2 [<CitationRef CitationID="CR87_10">87</CitationRef>, <CitationRef CitationID="CR88_10">88</CitationRef>] (see Table <InternalRef RefID="Tab2">10.2</InternalRef>). For example, the P30L and A49T mutants seemed to have a better response to dutasteride than finasteride, while F194L and P48R displayed higher affinity for the latter [<CitationRef CitationID="CR88_10">88</CitationRef>] (see Table <InternalRef RefID="Tab2">10.2</InternalRef>). The treatment with dutasteride is expected to be more efficient in the reduction of the enzyme activity in vivo than that with finasteride [<CitationRef CitationID="CR88_10">88</CitationRef>]. The results of these studies might help in the development of personalized medicine, including personalized prevention, for prostate cancer. Depending on the results of the REDUCT trial, the selection between finasteride and dutasteride as a preventive of CaP would be based on the genotype of SRD5A2.</Para>
            <Para TextBreak="No">The expression of SRD5A1 and SRD5A2 was tested in different normal and CaP cell lines of rat and human treated with finasteride and dutasteride [<CitationRef CitationID="CR39_10">39</CitationRef>]. In androgenic-responsive prostatic cancer (Dunning R-3327H) rats, the use of dutasteride, but not finasteride, inhibited CaP growth [<CitationRef CitationID="CR39_10">39</CitationRef>]. In BALB/c nude mice, daily oral treatment with finasteride was effective in inhibiting the growth of androgen-responsive human CaP cell line (LNCaP) xenografts; however, the results were not as clearcut as with dutasteride [<CitationRef CitationID="CR39_10">39</CitationRef>]. Dutasteride also enhanced in vivo therapeutic efficacy of castration [<CitationRef CitationID="CR39_10">39</CitationRef>]. This study shows that the inhibition of SRD5A1 and SRD5A2 by themselves is not enough to inhibit tumor growth, but it can be used as an additive to antiandrogen therapy.</Para>
            <Para TextBreak="No">The expression profile of 190 genes related to the androgen pathway was analyzed in nonresponsive (DU145) human CaP and LNCaP cell lines to evaluate the effects of dutasteride treatment [<CitationRef CitationID="CR89_10">89</CitationRef>]. The effect of dutasteride showed to be time-dependent and killed both cell lines at elevated doses [<CitationRef CitationID="CR89_10">89</CitationRef>]. A differential regulation of gene expression by dutasteride in LNCaP cells was observed [<CitationRef CitationID="CR89_10">89</CitationRef>]. Diverse genes were overexpressed in dutasteride-treated cells, including genes encoding proteins in androgen biosynthesis and metabolism (such as HSD17B1, HSD17B3, CYP11B2), signal transduction (ERBB2, VCAM, SOS1), androgen receptor and AR coregulators (AR, CCND1) (according to [<CitationRef CitationID="CR90_10">90</CitationRef>]), while androgen-regulated genes (ARGs) (such as KLK3, KLK2, DHCR24) were underexpressed [<CitationRef CitationID="CR89_10">89</CitationRef>]. Microarray data analysis was confirmed by quantitative real-time PCR assay [<CitationRef CitationID="CR89_10">89</CitationRef>]. The upregulation of the AR is a response to the decreased levels of DHT of the LNCaP cells when treated with dutasteride [<CitationRef CitationID="CR89_10">89</CitationRef>]. No differential gene expression was observed on DU145 cell line in dutasteride-treated cells because AR is required by cells to respond to this substance [<CitationRef CitationID="CR39_10">39</CitationRef>]. These findings show that AR-dependent cells treated with dutasteride decrease intracellular DHT concentration despite the active pathways that control androgen-independent growth [<CitationRef CitationID="CR89_10">89</CitationRef>].</Para>
            <Para TextBreak="No">The transcriptional response of LNCaP to MSA was investigated, and 951 genes, including cell-cycleregulators and androgen-regulated genes, with altered expression were identified [<CitationRef CitationID="CR91_10">91</CitationRef>]. The expression of AR and PSA at both mRNA and protein levels were decreased [<CitationRef CitationID="CR91_10">91</CitationRef>]. These results were confirmed in different human cell lines (LNCaP, LAPC-4, CWR22Rv1, LNCaP-C81, and LNCaP-LN3) where a decrease in AR and PSA expression was observed, independent of the AR genotypes or sensitivity to androgen-stimulated growth [<CitationRef CitationID="CR92_10">92</CitationRef>]. Diverse AR-regulated genes implicated in prostate carcinogenesis (PSA, KLK2, ABCC4, DHCR24, and GUCY1A3) were inhibited by MSA, but this could be attenuated by the overexpression of AR [<CitationRef CitationID="CR92_10">92</CitationRef>]. MSA seems to reduce AR availability by blocking AR transcription. In conjunction, these results indicate that MSA may protect against CaP by modulating the expression of AR and AR-regulated genes.</Para>
            <Para TextBreak="No">A positive association between men with PCP and presence of the A allele in a 10 kb upstream substitution of the AR gene was observed when patients who received hormonal therapy as primary treatment at diagnosis were assessed [<CitationRef CitationID="CR93_10">93</CitationRef>]. There was no correlation between this polymorphism and other variables, such as Gleason score [<CitationRef CitationID="CR93_10">93</CitationRef>]. It is possible that AR genotypes may affect the response to hormonal treatment and CaP death [<CitationRef CitationID="CR93_10">93</CitationRef>]. Recently, 529 advanced prostate cancer patients treated with ADT (orchiectomy or luteinizing hormone-releasing therapy with or without antiandrogen) were genotyped for 129 polymorphisms (SNPs and microsatellite repeats) in 20 genes in the androgen synthesis and metabolism [<CitationRef CitationID="CR94_10">94</CitationRef>]. Three polymorphisms showed positive association with time to progression (TTP) during ADT in the <Emphasis Type="Italic">CYP19A1</Emphasis> (a SNP 5 kb upstream of the gene), <Emphasis Type="Italic">HSD3B1</Emphasis> (a SNP 13 kb upstream of the gene), and <Emphasis Type="Italic">HSD17B4</Emphasis>(an intronic SNP) genes [<CitationRef CitationID="CR94_10">94</CitationRef>]. Progression was described as two proven increases in PSA levels or initiation of secondary hormonal therapy for rising PSA [<CitationRef CitationID="CR94_10">94</CitationRef>]. Individuals homozygous for <Emphasis Type="Italic">HSD17B4</Emphasis> (C/C) presented lower PSA values at ADT initiation than the other genotypes. Patients who carried more than one of these polymorphisms presented a better response to the treatment (34 months) compared to the ones with any favorable alleles (11.8 months) [<CitationRef CitationID="CR94_10">94</CitationRef>]. On this basis, the efficacy of ADT was hypothesized to be improved by drugs that inhibit or increase these targets [<CitationRef CitationID="CR94_10">94</CitationRef>]. These polymorphisms, however, were not evaluated in relation to their functional enzymatic consequences.</Para>
            <Para TextBreak="No">Also the genotypes of the <Emphasis Type="Italic">SLCO1B3</Emphasis> gene were evaluated in 68 Caucasian patients with advanced CaP in relation to the interval of ADT to androgen independence [<CitationRef CitationID="CR95_10">95</CitationRef>]. These patients enrolled in a clinical trial using ketoconazole with or without alendronate or in a clinical trial of docetaxel with or without thalidomide [<CitationRef CitationID="CR95_10">95</CitationRef>]. The presence of the wild-type allele (T) of S112A polymorphism was associated with a shorter time to androgen independence in both ADT with metastatic disease and biochemical failure with no metastatic disease [<CitationRef CitationID="CR95_10">95</CitationRef>]. This association was confirmed even in combined analysis of the two groups stratified by stage [<CitationRef CitationID="CR95_10">95</CitationRef>]. These findings, if replicated, can have potential implications in the evaluation of response to hormonal therapy.</Para>
          </Section1>
          <Section1 ID="Sec12" Type="Conclusion">
            <Heading>Conclusions</Heading>
            <Para TextBreak="No">Nowadays, many genes are recognized to be involved in CaP progression and development. Detailed knowledge of polymorphisms and biochemical variation of these genes has implications for the identification of presymptomatic but at-risk men and the development and selection of drugs to treat the cancer in a personalized manner or even prevent the disease in an individualized fashion.</Para>
            <Para TextBreak="No">Despite the accumulating knowledge of polymorphisms in genes in the androgen pathway, their biochemical characterization, and their relation to CaP, there is a lack in pharmacogenetic studies of most drugs currently in use. The few reports available at the moment have to be replicated in independent and larger samples. New targets for CaP prevention and treatment, such as SRD5A1 and the gene fusions, are available for investigation, but their effects in the disease are not totally understood yet.</Para>
            <Para TextBreak="No">In summary, we have reviewed here the DNA variation in prostate cancer candidate genes in the androgen pathway and pharmacogenetic studies available at the moment. Molecular research in chemoprevention and therapy of CaP might lead to impressive pharmacological advances in the next few years.</Para>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-829-4_Chapter_10.pdf" OutputMedium="Online" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Acknowledgments>
            <Heading>Acknowledgment</Heading>
            <SimplePara>JKVR is a Medical Foundation Fellow at the University of Sydney. The work in his laboratory is also supported in part by NCI grant P01 CA108964 (project 1 to JKVR).</SimplePara>
          </Acknowledgments>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1_10">
              <CitationNumber>1.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SP</Initials>
                  <FamilyName>Balk</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KE</Initials>
                  <FamilyName>Knudsen</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">AR, the cell cycle, and prostate cancer</ArticleTitle>
                <JournalTitle>Nucl Recept Signal</JournalTitle>
                <VolumeID>6</VolumeID>
                <FirstPage>e001</FirstPage>
                <Occurrence Type="PID">
                  <Handle>18301781</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1621/nrs.06001</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Balk SP, Knudsen KE. AR, the cell cycle, and prostate cancer. Nucl Recept Signal 2008;6:e001.</BibUnstructured>
            </Citation>
            <Citation ID="CR2_10">
              <CitationNumber>2.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AS</Initials>
                  <FamilyName>Wright</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RC</Initials>
                  <FamilyName>Douglas</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LN</Initials>
                  <FamilyName>Thomas</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CB</Initials>
                  <FamilyName>Lazier</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RS</Initials>
                  <FamilyName>Rittmaster</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase</ArticleTitle>
                <JournalTitle>Endocrinology</JournalTitle>
                <VolumeID>140</VolumeID>
                <FirstPage>4509</FirstPage>
                <LastPage>15</LastPage>
                <Occurrence Type="PID">
                  <Handle>10499505</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/en.140.10.4509</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXmtFGru7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wright AS, Douglas RC, Thomas LN, Lazier CB, Rittmaster RS. Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase. Endocrinology 1999;140:4509–15.</BibUnstructured>
            </Citation>
            <Citation ID="CR3_10">
              <CitationNumber>3.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Luu-The</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Bélanger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Labrie</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Androgen biosynthetic pathways in the human prostate</ArticleTitle>
                <JournalTitle>Best Pract Res Clin Endocrinol Metab</JournalTitle>
                <VolumeID>22</VolumeID>
                <FirstPage>207</FirstPage>
                <LastPage>21</LastPage>
                <Occurrence Type="PID">
                  <Handle>18471780</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.beem.2008.01.008</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXlslygsbg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Luu-The V, Bélanger A, Labrie F. Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab 2008;22:207–21.</BibUnstructured>
            </Citation>
            <Citation ID="CR4_10">
              <CitationNumber>4.</CitationNumber>
              <BibBook>
                <InstitutionalAuthorName>Australian Institute of Health and Welfare</InstitutionalAuthorName>
                <Year>2008</Year>
                <BookTitle>Australia’s health 2008</BookTitle>
                <PublisherName>AIHW</PublisherName>
                <PublisherLocation>Canberra</PublisherLocation>
                <BibComments>Cat. no. AUS 99</BibComments>
              </BibBook>
              <BibUnstructured>Australian Institute of Health and Welfare. Australia’s health 2008. Canberra: AIHW; 2008. Cat. no. AUS 99.</BibUnstructured>
            </Citation>
            <Citation ID="CR5_10">
              <CitationNumber>5.</CitationNumber>
              <BibBook>
                <InstitutionalAuthorName>American Cancer Society</InstitutionalAuthorName>
                <Year>2008</Year>
                <BookTitle>Cancer facts &amp; figures 2008</BookTitle>
                <PublisherName>American Cancer Society</PublisherName>
                <PublisherLocation>Atlanta</PublisherLocation>
              </BibBook>
              <BibUnstructured>American Cancer Society. Cancer facts &amp; figures 2008. Atlanta: American Cancer Society; 2008.</BibUnstructured>
            </Citation>
            <Citation ID="CR6_10">
              <CitationNumber>6.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CP</Initials>
                  <FamilyName>Wu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FL</Initials>
                  <FamilyName>Gu</FamilyName>
                </BibAuthorName>
                <Year>1991</Year>
                <ArticleTitle Language="En">The prostate in eunuchs</ArticleTitle>
                <JournalTitle>Prog Clin Biol Res</JournalTitle>
                <VolumeID>370</VolumeID>
                <FirstPage>249</FirstPage>
                <LastPage>55</LastPage>
                <Occurrence Type="PID">
                  <Handle>1924456</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK38%2FitFWitA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wu CP, Gu FL. The prostate in eunuchs. Prog Clin Biol Res 1991;370:249–55.</BibUnstructured>
            </Citation>
            <Citation ID="CR7_10">
              <CitationNumber>7.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MH</Initials>
                  <FamilyName>Eng</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LG</Initials>
                  <FamilyName>Charles</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BD</Initials>
                  <FamilyName>Ross</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CE</Initials>
                  <FamilyName>Chrisp</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KJ</Initials>
                  <FamilyName>Pienta</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NM</Initials>
                  <FamilyName>Greenberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CX</Initials>
                  <FamilyName>Hsu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MG</Initials>
                  <FamilyName>Sanda</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Early castration reduces prostatic carcinogenesis in transgenic mice</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>54</VolumeID>
                <FirstPage>1112</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>10604719</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0090-4295(99)00297-6</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3c%2FmvVaiuw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Eng MH, Charles LG, Ross BD, Chrisp CE, Pienta KJ, Greenberg NM, et al. Early castration reduces prostatic carcinogenesis in transgenic mice. Urology 1999;54:1112–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR8_10">
              <CitationNumber>8.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Lu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SY</Initials>
                  <FamilyName>Tsai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Tsai</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>57</VolumeID>
                <FirstPage>4511</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>9377562</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXmslKqt7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lu S, Tsai SY, Tsai MJ. Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Res 1997;57:4511–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR9_10">
              <CitationNumber>9.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DA</Initials>
                  <FamilyName>Loblaw</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KS</Initials>
                  <FamilyName>Virgo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Nam</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Somerfield</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Ben-Josef</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DS</Initials>
                  <FamilyName>Mendelson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Middleton</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SA</Initials>
                  <FamilyName>Sharp</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TJ</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Talcott</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Taplin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NJ</Initials>
                  <FamilyName>Vogelzang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Wade</FamilyName>
                  <Suffix>III</Suffix>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CL</Initials>
                  <FamilyName>Bennett</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HI</Initials>
                  <FamilyName>Scher</FamilyName>
                </BibAuthorName>
                <InstitutionalAuthorName>American Society of Clinical Oncology</InstitutionalAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>25</VolumeID>
                <FirstPage>1596</FirstPage>
                <LastPage>605</LastPage>
                <Occurrence Type="PID">
                  <Handle>17404365</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2006.10.1949</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXlsVynurs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007;25:1596–605.</BibUnstructured>
            </Citation>
            <Citation ID="CR10_10">
              <CitationNumber>10.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JE</Initials>
                  <FamilyName>Damber</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Aus</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Prostate cancer</ArticleTitle>
                <JournalTitle>Lancet</JournalTitle>
                <VolumeID>371</VolumeID>
                <FirstPage>1710</FirstPage>
                <LastPage>21</LastPage>
                <Occurrence Type="PID">
                  <Handle>18486743</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0140-6736(08)60729-1</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Damber JE, Aus G. Prostate cancer. Lancet 2008;371:1710–21.</BibUnstructured>
            </Citation>
            <Citation ID="CR11_10">
              <CitationNumber>11.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Huggins</FamilyName>
                </BibAuthorName>
                <Year>1942</Year>
                <ArticleTitle Language="En">Effect of orchiectomy and irradiation on cancer of the prostate</ArticleTitle>
                <JournalTitle>Ann Surg</JournalTitle>
                <VolumeID>115</VolumeID>
                <FirstPage>1192</FirstPage>
                <LastPage>200</LastPage>
                <Occurrence Type="PID">
                  <Handle>17858048</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/00000658-194206000-00030</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD2srktlWiug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Huggins C. Effect of orchiectomy and irradiation on cancer of the prostate. Ann Surg 1942;115:1192–200.</BibUnstructured>
            </Citation>
            <Citation ID="CR12_10">
              <CitationNumber>12.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JR</Initials>
                  <FamilyName>Carlin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Höglund</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LO</Initials>
                  <FamilyName>Eriksson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Christofalo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SL</Initials>
                  <FamilyName>Gregoire</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Taylor</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KE</Initials>
                  <FamilyName>Andersson</FamilyName>
                </BibAuthorName>
                <Year>1992</Year>
                <ArticleTitle Language="En">Disposition and pharmacokinetics of [<Superscript>14</Superscript>C]finasteride after oral administration in humans</ArticleTitle>
                <JournalTitle>Drug Metab Dispos</JournalTitle>
                <VolumeID>20</VolumeID>
                <FirstPage>48</FirstPage>
                <LastPage>55</LastPage>
              </BibArticle>
              <BibUnstructured>Carlin JR, Höglund P, Eriksson LO, Christofalo P, Gregoire SL, Taylor AM, et al. Disposition and pharmacokinetics of [<Superscript>14</Superscript>C]finasteride after oral administration in humans. Drug Metab Dispos 1992;20:48–55.</BibUnstructured>
            </Citation>
            <Citation ID="CR13_10">
              <CitationNumber>13.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Tian</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RA</Initials>
                  <FamilyName>Mook</FamilyName>
                  <Suffix>Jr</Suffix>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ML</Initials>
                  <FamilyName>Moss</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SV</Initials>
                  <FamilyName>Frye</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Mechanism of time-dependent inhibition of 5 alpha-reductases by delta 1-4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand-binding energies</ArticleTitle>
                <JournalTitle>Biochemistry</JournalTitle>
                <VolumeID>34</VolumeID>
                <FirstPage>13453</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>7577933</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1021/bi00041a024</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXot1yks7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tian G, Mook Jr RA, Moss ML, Frye SV. Mechanism of time-dependent inhibition of 5 alpha-reductases by delta 1-4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand-binding energies. Biochemistry 1995;34:13453–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR14_10">
              <CitationNumber>14.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IM</Initials>
                  <FamilyName>Thompson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PJ</Initials>
                  <FamilyName>Goodman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Tangen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MS</Initials>
                  <FamilyName>Lucia</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GJ</Initials>
                  <FamilyName>Miller</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LG</Initials>
                  <FamilyName>Ford</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MM</Initials>
                  <FamilyName>Lieber</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RD</Initials>
                  <FamilyName>Cespedes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JN</Initials>
                  <FamilyName>Atkins</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Lippman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Carlin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Ryan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Szczepanek</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JJ</Initials>
                  <FamilyName>Crowley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CA</Initials>
                  <FamilyName>Coltman</FamilyName>
                  <Suffix>Jr</Suffix>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">The influence of finasteride on the development of prostate cancer</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>349</VolumeID>
                <FirstPage>215</FirstPage>
                <LastPage>24</LastPage>
                <Occurrence Type="PID">
                  <Handle>12824459</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMoa030660</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXlsVGjsbs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215–24.</BibUnstructured>
            </Citation>
            <Citation ID="CR15_10">
              <CitationNumber>15.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MS</Initials>
                  <FamilyName>Lucia</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JI</Initials>
                  <FamilyName>Epstein</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PJ</Initials>
                  <FamilyName>Goodman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AK</Initials>
                  <FamilyName>Darke</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>VE</Initials>
                  <FamilyName>Reuter</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Civantos</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Tangen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HL</Initials>
                  <FamilyName>Parnes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Lippman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FG</Initials>
                  <FamilyName>Rosa</FamilyName>
                  <Particle>La</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MW</Initials>
                  <FamilyName>Kattan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ED</Initials>
                  <FamilyName>Crawford</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LG</Initials>
                  <FamilyName>Ford</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CA</Initials>
                  <FamilyName>Coltman</FamilyName>
                  <Suffix>Jr</Suffix>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>IM</Initials>
                  <FamilyName>Thompson</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>99</VolumeID>
                <FirstPage>1375</FirstPage>
                <LastPage>83</LastPage>
                <Occurrence Type="PID">
                  <Handle>17848673</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/djm117</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXht1aiu7vO</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1375–83.</BibUnstructured>
            </Citation>
            <Citation ID="CR16_10">
              <CitationNumber>16.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IM</Initials>
                  <FamilyName>Thompson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Tangen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PJ</Initials>
                  <FamilyName>Goodman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MS</Initials>
                  <FamilyName>Lucia</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HL</Initials>
                  <FamilyName>Parnes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Lippman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CA</Initials>
                  <FamilyName>Coltman</FamilyName>
                  <Suffix>Jr</Suffix>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>177</VolumeID>
                <FirstPage>1749</FirstPage>
                <LastPage>52</LastPage>
                <Occurrence Type="PID">
                  <Handle>17437804</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.juro.2007.01.071</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXlsV2jtLY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Parnes HL, Lippman SM, et al. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol 2007;177:1749–52.</BibUnstructured>
            </Citation>
            <Citation ID="CR17_10">
              <CitationNumber>17.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Canby-Hagino</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Hernandez</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TC</Initials>
                  <FamilyName>Brand</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Thompson</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Looking back at PCPT: looking forward to new paradigms in prostate cancer screening and prevention</ArticleTitle>
                <JournalTitle>Eur Urol</JournalTitle>
                <VolumeID>51</VolumeID>
                <FirstPage>27</FirstPage>
                <LastPage>33</LastPage>
                <Occurrence Type="PID">
                  <Handle>17030406</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.eururo.2006.09.002</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Canby-Hagino E, Hernandez J, Brand TC, Thompson I. Looking back at PCPT: looking forward to new paradigms in prostate cancer screening and prevention. Eur Urol 2007;51:27–33.</BibUnstructured>
            </Citation>
            <Citation ID="CR18_10">
              <CitationNumber>18.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HC</Initials>
                  <FamilyName>Evans</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KL</Initials>
                  <FamilyName>Goa</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Dutasteride</ArticleTitle>
                <JournalTitle>Drugs Aging</JournalTitle>
                <VolumeID>20</VolumeID>
                <FirstPage>905</FirstPage>
                <LastPage>16</LastPage>
                <Occurrence Type="PID">
                  <Handle>14565784</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.2165/00002512-200320120-00005</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXpt1Omtrc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Evans HC, Goa KL. Dutasteride. Drugs Aging 2003;20:905–16.</BibUnstructured>
            </Citation>
            <Citation ID="CR19_10">
              <CitationNumber>19.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RV</Initials>
                  <FamilyName>Clark</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Hermann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GR</Initials>
                  <FamilyName>Cunningham</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TH</Initials>
                  <FamilyName>Wilson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BB</Initials>
                  <FamilyName>Morrill</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Hobbs</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor</ArticleTitle>
                <JournalTitle>J Clin Endocrinol Metab</JournalTitle>
                <VolumeID>89</VolumeID>
                <FirstPage>2179</FirstPage>
                <LastPage>84</LastPage>
                <Occurrence Type="PID">
                  <Handle>15126539</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/jc.2003-030330</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXjvFyrt74%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 2004;89:2179–84.</BibUnstructured>
            </Citation>
            <Citation ID="CR20_10">
              <CitationNumber>20.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CB</Initials>
                  <FamilyName>Lazier</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LN</Initials>
                  <FamilyName>Thomas</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RC</Initials>
                  <FamilyName>Douglas</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JP</Initials>
                  <FamilyName>Vessey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RS</Initials>
                  <FamilyName>Rittmaster</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>58</VolumeID>
                <FirstPage>130</FirstPage>
                <LastPage>44</LastPage>
                <Occurrence Type="PID">
                  <Handle>14716738</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.10340</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhvVKjs70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lazier CB, Thomas LN, Douglas RC, Vessey JP, Rittmaster RS. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. Prostate 2004;58:130–44.</BibUnstructured>
            </Citation>
            <Citation ID="CR21_10">
              <CitationNumber>21.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Maria McCrohan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Morrissey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>O’Keane</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Mulligan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Watson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Fitzpatrick</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RW</Initials>
                  <FamilyName>Watson</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Effects of the dual 5 alpha-reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>106</VolumeID>
                <FirstPage>2743</FirstPage>
                <LastPage>52</LastPage>
                <Occurrence Type="PID">
                  <Handle>16703599</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/cncr.21938</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Maria McCrohan A, Morrissey C, O’Keane C, Mulligan N, Watson C, Smith J, et al. Effects of the dual 5 alpha-reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines. Cancer 2006;106:2743–52.</BibUnstructured>
            </Citation>
            <Citation ID="CR22_10">
              <CitationNumber>22.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Musquera</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NE</Initials>
                  <FamilyName>Fleshner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Finelli</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AR</Initials>
                  <FamilyName>Zlotta</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride</ArticleTitle>
                <JournalTitle>Expert Rev Anticancer Ther</JournalTitle>
                <VolumeID>8</VolumeID>
                <FirstPage>1073</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>18588452</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1586/14737140.8.7.1073</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXnslyrtbc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Musquera M, Fleshner NE, Finelli A, Zlotta AR. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride. Expert Rev Anticancer Ther 2008;8:1073–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR23_10">
              <CitationNumber>23.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>XY</Initials>
                  <FamilyName>Zhao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PJ</Initials>
                  <FamilyName>Malloy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Krishnan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Swami</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NM</Initials>
                  <FamilyName>Navone</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DM</Initials>
                  <FamilyName>Peehl</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Feldman</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor</ArticleTitle>
                <JournalTitle>Nat Med</JournalTitle>
                <VolumeID>6</VolumeID>
                <FirstPage>703</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>10835690</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/76287</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXkt12itrw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 2000;6:703–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR24_10">
              <CitationNumber>24.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SO</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Yeon Chun</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Nadiminty</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Trump</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Ip</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Dong</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AC</Initials>
                  <FamilyName>Gao</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA)</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>66</VolumeID>
                <FirstPage>1070</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>16637076</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.20329</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28Xnt1CntLs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lee SO, Yeon Chun J, Nadiminty N, Trump DL, Ip C, Dong Y, et al. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). Prostate 2006;66:1070–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR25_10">
              <CitationNumber>25.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Zhang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Ni</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EM</Initials>
                  <FamilyName>Messing</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Chang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CR</Initials>
                  <FamilyName>Yang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Yeh</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>99</VolumeID>
                <FirstPage>7408</FirstPage>
                <LastPage>13</LastPage>
                <Occurrence Type="PID">
                  <Handle>12032296</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.102014399</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XktlCktLk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zhang Y, Ni J, Messing EM, Chang E, Yang CR, Yeh S. Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells. Proc Natl Acad Sci U S A 2002;99:7408–13.</BibUnstructured>
            </Citation>
            <Citation ID="CR26_10">
              <CitationNumber>26.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EA</Initials>
                  <FamilyName>Klein</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Selenium and vitamin E cancer prevention trial</ArticleTitle>
                <JournalTitle>Ann N Y Acad Sci</JournalTitle>
                <VolumeID>1031</VolumeID>
                <FirstPage>234</FirstPage>
                <LastPage>41</LastPage>
                <Occurrence Type="PID">
                  <Handle>15753149</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1196/annals.1331.023</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXivFWnu7w%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Klein EA. Selenium and vitamin E cancer prevention trial. Ann N Y Acad Sci 2004;1031:234–41.</BibUnstructured>
            </Citation>
            <Citation ID="CR27_10">
              <CitationNumber>27.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>EP</Initials>
                  <FamilyName>Gelmann</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Molecular biology of the androgen receptor</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>20</VolumeID>
                <FirstPage>3001</FirstPage>
                <LastPage>15</LastPage>
                <Occurrence Type="PID">
                  <Handle>12089231</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2002.10.018</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38Xlslyrt7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002;20:3001–15.</BibUnstructured>
            </Citation>
            <Citation ID="CR28_10">
              <CitationNumber>28.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Dehm</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Tindall</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Androgen receptor structural and functional elements: role and regulation in prostate cancer</ArticleTitle>
                <JournalTitle>Mol Endocrinol</JournalTitle>
                <VolumeID>21</VolumeID>
                <FirstPage>2855</FirstPage>
                <LastPage>63</LastPage>
                <Occurrence Type="PID">
                  <Handle>17636035</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/me.2007-0223</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhsVeit7nP</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dehm SM, Tindall DJ. Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol Endocrinol 2007;21:2855–63.</BibUnstructured>
            </Citation>
            <Citation ID="CR29_10">
              <CitationNumber>29.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Sarvis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>IM</Initials>
                  <FamilyName>Thompson</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Androgens and prevention of prostate cancer</ArticleTitle>
                <JournalTitle>Curr Opin Endocrinol Diabetes Obes</JournalTitle>
                <VolumeID>15</VolumeID>
                <FirstPage>271</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>18438176</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/MED.0b013e3282fc7038</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXlvFantbk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sarvis JA, Thompson IM. Androgens and prevention of prostate cancer. Curr Opin Endocrinol Diabetes Obes 2008;15:271–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR30_10">
              <CitationNumber>30.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Wako</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Kawasaki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Yamana</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Suzuki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Jiang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Umezu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Nishiyama</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Takahashi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Hamakubo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Kodama</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Naito</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Pathol</JournalTitle>
                <VolumeID>61</VolumeID>
                <FirstPage>448</FirstPage>
                <LastPage>54</LastPage>
                <Occurrence Type="PID">
                  <Handle>17720776</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1136/jcp.2007.050906</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXlsFegsbk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wako K, Kawasaki T, Yamana K, Suzuki K, Jiang S, Umezu H, et al. Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer. J Clin Pathol 2008;61:448–54.</BibUnstructured>
            </Citation>
            <Citation ID="CR31_10">
              <CitationNumber>31.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AS</Initials>
                  <FamilyName>Singh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CH</Initials>
                  <FamilyName>Chau</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DK</Initials>
                  <FamilyName>Price</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Figg</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Mechanisms of disease: polymorphisms of androgen regulatory genes in the development of prostate cancer</ArticleTitle>
                <JournalTitle>Nat Clin Pract Urol</JournalTitle>
                <VolumeID>2</VolumeID>
                <FirstPage>101</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>16474655</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/ncpuro0091</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXjsFaksrY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Singh AS, Chau CH, Price DK, Figg WD. Mechanisms of disease: polymorphisms of androgen regulatory genes in the development of prostate cancer. Nat Clin Pract Urol 2005;2:101–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR32_10">
              <CitationNumber>32.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MP</Initials>
                  <FamilyName>Zeegers</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LA</Initials>
                  <FamilyName>Kiemeney</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Nieder</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Ostrer</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk?</ArticleTitle>
                <JournalTitle>Cancer Epidemiol Biomarkers Prev</JournalTitle>
                <VolumeID>13</VolumeID>
                <FirstPage>1765</FirstPage>
                <LastPage>71</LastPage>
                <Occurrence Type="PID">
                  <Handle>15533905</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXpsVSktL0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zeegers MP, Kiemeney LA, Nieder AM, Ostrer H. How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk? Cancer Epidemiol Biomarkers Prev 2004;13:1765–71.</BibUnstructured>
            </Citation>
            <Citation ID="CR33_10">
              <CitationNumber>33.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>D’Amico</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Biancolella</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Margiotti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JK</Initials>
                  <FamilyName>Reichardt</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Novelli</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Genomic biomarkers, androgen pathway and prostate cancer</ArticleTitle>
                <JournalTitle>Pharmacogenomics</JournalTitle>
                <VolumeID>8</VolumeID>
                <FirstPage>645</FirstPage>
                <LastPage>61</LastPage>
                <Occurrence Type="PID">
                  <Handle>17559353</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.2217/14622416.8.6.645</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>D’Amico F, Biancolella M, Margiotti K, Reichardt JK, Novelli G. Genomic biomarkers, androgen pathway and prostate cancer. Pharmacogenomics 2007;8:645–61.</BibUnstructured>
            </Citation>
            <Citation ID="CR34_10">
              <CitationNumber>34.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Normington</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DW</Initials>
                  <FamilyName>Russell</FamilyName>
                </BibAuthorName>
                <Year>1992</Year>
                <ArticleTitle Language="En">Tissue distribution and kinetic characteristics of rat steroid 5 alpha-reductase isozymes. Evidence for distinct physiological functions</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>267</VolumeID>
                <FirstPage>19548</FirstPage>
                <LastPage>54</LastPage>
                <Occurrence Type="PID">
                  <Handle>1527072</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3sXktVWisrY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Normington K, Russell DW. Tissue distribution and kinetic characteristics of rat steroid 5 alpha-reductase isozymes. Evidence for distinct physiological functions. J Biol Chem 1992;267:19548–54.</BibUnstructured>
            </Citation>
            <Citation ID="CR35_10">
              <CitationNumber>35.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AE</Initials>
                  <FamilyName>Thigpen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RI</Initials>
                  <FamilyName>Silver</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Guileyardo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ML</Initials>
                  <FamilyName>Casey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>McConnell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DW</Initials>
                  <FamilyName>Russell</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression</ArticleTitle>
                <JournalTitle>J Clin Invest</JournalTitle>
                <VolumeID>92</VolumeID>
                <FirstPage>903</FirstPage>
                <LastPage>10</LastPage>
                <Occurrence Type="PID">
                  <Handle>7688765</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1172/JCI116665</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXhtVaqtLw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest 1993;92:903–10.</BibUnstructured>
            </Citation>
            <Citation ID="CR36_10">
              <CitationNumber>36.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Uemura</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Tamura</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Chung</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Honma</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Okuyama</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Nakamura</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Nakagawa</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Sci</JournalTitle>
                <VolumeID>99</VolumeID>
                <FirstPage>81</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>17986282</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXnsFWmtA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Uemura M, Tamura K, Chung S, Honma S, Okuyama A, Nakamura Y, et al. Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci 2008;99:81–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR37_10">
              <CitationNumber>37.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LN</Initials>
                  <FamilyName>Thomas</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CB</Initials>
                  <FamilyName>Lazier</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Gupta</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RW</Initials>
                  <FamilyName>Norman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DA</Initials>
                  <FamilyName>Troyer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SP</Initials>
                  <FamilyName>O’Brien</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RS</Initials>
                  <FamilyName>Rittmaster</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>63</VolumeID>
                <FirstPage>231</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>15538746</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.20188</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXktFyltL8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Thomas LN, Lazier CB, Gupta R, Norman RW, Troyer DA, O’Brien SP, et al. Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 2005;63:231–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR38_10">
              <CitationNumber>38.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LN</Initials>
                  <FamilyName>Thomas</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RC</Initials>
                  <FamilyName>Douglas</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CB</Initials>
                  <FamilyName>Lazier</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Gupta</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RW</Initials>
                  <FamilyName>Norman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PR</Initials>
                  <FamilyName>Murphy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RS</Initials>
                  <FamilyName>Rittmaster</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CK</Initials>
                  <FamilyName>Too</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer</ArticleTitle>
                <JournalTitle>J Urol</JournalTitle>
                <VolumeID>179</VolumeID>
                <FirstPage>147</FirstPage>
                <LastPage>51</LastPage>
                <Occurrence Type="PID">
                  <Handle>17997435</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.juro.2007.08.155</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Thomas LN, Douglas RC, Lazier CB, Gupta R, Norman RW, Murphy PR, et al. Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer. J Urol 2008;179:147–51.</BibUnstructured>
            </Citation>
            <Citation ID="CR39_10">
              <CitationNumber>39.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Xu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SL</Initials>
                  <FamilyName>Dalrymple</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RE</Initials>
                  <FamilyName>Becker</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SR</Initials>
                  <FamilyName>Denmeade</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JT</Initials>
                  <FamilyName>Isaacs</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>12</VolumeID>
                <FirstPage>4072</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>16818707</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-06-0184</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XmsVaksr0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res 2006;12:4072–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR40_10">
              <CitationNumber>40.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Söderström</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Wadelius</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SO</Initials>
                  <FamilyName>Andersson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JE</Initials>
                  <FamilyName>Johansson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Johansson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Granath</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Rane</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">5alpha-reductase 2 polymorphisms as risk factors in prostate cancer</ArticleTitle>
                <JournalTitle>Pharmacogenetics</JournalTitle>
                <VolumeID>12</VolumeID>
                <FirstPage>307</FirstPage>
                <LastPage>12</LastPage>
                <Occurrence Type="PID">
                  <Handle>12042668</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/00008571-200206000-00006</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Söderström T, Wadelius M, Andersson SO, Johansson JE, Johansson S, Granath F, et al. 5alpha-reductase 2 polymorphisms as risk factors in prostate cancer. Pharmacogenetics 2002;12:307–12.</BibUnstructured>
            </Citation>
            <Citation ID="CR41_10">
              <CitationNumber>41.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Luo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TA</Initials>
                  <FamilyName>Dunn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Ewing</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PC</Initials>
                  <FamilyName>Walsh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WB</Initials>
                  <FamilyName>Isaacs</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>57</VolumeID>
                <FirstPage>134</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>12949937</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.10284</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXosFKqtL4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Luo J, Dunn TA, Ewing CM, Walsh PC, Isaacs WB. Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. Prostate 2003;57:134–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR42_10">
              <CitationNumber>42.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Titus</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CW</Initials>
                  <FamilyName>Gregory</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>OH</Initials>
                  <FamilyName>Ford</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Schell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SJ</Initials>
                  <FamilyName>Maygarden</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Mohler</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>11</VolumeID>
                <FirstPage>4365</FirstPage>
                <LastPage>71</LastPage>
                <Occurrence Type="PID">
                  <Handle>15958619</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-04-0738</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXltFelu7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Titus MA, Gregory CW, Ford OH, Schell MJ, Maygarden SJ, Mohler JL. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 2005;11:4365–71.</BibUnstructured>
            </Citation>
            <Citation ID="CR43_10">
              <CitationNumber>43.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>NM</Initials>
                  <FamilyName>Makridakis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RK</Initials>
                  <FamilyName>Ross</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Pike</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LE</Initials>
                  <FamilyName>Crocitto</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LN</Initials>
                  <FamilyName>Kolonel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CL</Initials>
                  <FamilyName>Pearce</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BE</Initials>
                  <FamilyName>Henderson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JK</Initials>
                  <FamilyName>Reichardt</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA</ArticleTitle>
                <JournalTitle>Lancet</JournalTitle>
                <VolumeID>354</VolumeID>
                <FirstPage>975</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>10501358</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0140-6736(98)11282-5</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXmslWks7k%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, et al. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 1999;354:975–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR44_10">
              <CitationNumber>44.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>NM</Initials>
                  <FamilyName>Makridakis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Salle</FamilyName>
                  <Particle>di</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JK</Initials>
                  <FamilyName>Reichardt</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II</ArticleTitle>
                <JournalTitle>Pharmacogenetics</JournalTitle>
                <VolumeID>10</VolumeID>
                <FirstPage>407</FirstPage>
                <LastPage>13</LastPage>
                <Occurrence Type="PID">
                  <Handle>10898110</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1097/00008571-200007000-00004</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXlt1yjs7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Makridakis NM, di Salle E, Reichardt JK. Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II. Pharmacogenetics 2000;10:407–13.</BibUnstructured>
            </Citation>
            <Citation ID="CR45_10">
              <CitationNumber>45.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Ntais</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Polycarpou</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JP</Initials>
                  <FamilyName>Ioannidis</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis</ArticleTitle>
                <JournalTitle>Cancer Epidemiol Biomarkers Prev</JournalTitle>
                <VolumeID>12</VolumeID>
                <FirstPage>618</FirstPage>
                <LastPage>24</LastPage>
                <Occurrence Type="PID">
                  <Handle>12869400</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXlsVymsbo%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ntais C, Polycarpou A, Ioannidis JP. SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2003;12:618–24.</BibUnstructured>
            </Citation>
            <Citation ID="CR46_10">
              <CitationNumber>46.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CL</Initials>
                  <FamilyName>Pearce</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Berg</FamilyName>
                  <Particle>Van Den</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Makridakis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JK</Initials>
                  <FamilyName>Reichardt</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RK</Initials>
                  <FamilyName>Ross</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Pike</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LN</Initials>
                  <FamilyName>Kolonel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BE</Initials>
                  <FamilyName>Henderson</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">No association between the SRD5A2 Gene A49T missense variant and prostate cancer risk: lessons learned</ArticleTitle>
                <JournalTitle>Hum Mol Genet</JournalTitle>
                <VolumeID>17</VolumeID>
                <IssueID>16</IssueID>
                <FirstPage>2456</FirstPage>
                <LastPage>61</LastPage>
                <Occurrence Type="PID">
                  <Handle>18469342</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/hmg/ddn145</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXptVert70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Pearce CL, Van Den Berg DJ, Makridakis N, Reichardt JK, Ross RK, Pike MC, et al. No association between the SRD5A2 Gene A49T missense variant and prostate cancer risk: lessons learned. Hum Mol Genet 2008;17(16):2456–61.</BibUnstructured>
            </Citation>
            <Citation ID="CR47_10">
              <CitationNumber>47.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Makridakis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RK</Initials>
                  <FamilyName>Ross</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Pike</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Chang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FZ</Initials>
                  <FamilyName>Stanczyk</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LN</Initials>
                  <FamilyName>Kolonel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CY</Initials>
                  <FamilyName>Shi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Yu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BE</Initials>
                  <FamilyName>Henderson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JK</Initials>
                  <FamilyName>Reichardt</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>57</VolumeID>
                <FirstPage>1020</FirstPage>
                <LastPage>2</LastPage>
                <Occurrence Type="PID">
                  <Handle>9067262</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXhvFOis74%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Makridakis N, Ross RK, Pike MC, Chang L, Stanczyk FZ, Kolonel LN, et al. A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase. Cancer Res 1997;57:1020–2.</BibUnstructured>
            </Citation>
            <Citation ID="CR48_10">
              <CitationNumber>48.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Davis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DW</Initials>
                  <FamilyName>Russell</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Unusual length polymorphism in human steroid 5 alpha-reductase type 2 gene (SRD5A2)</ArticleTitle>
                <JournalTitle>Hum Mol Genet</JournalTitle>
                <VolumeID>2</VolumeID>
                <FirstPage>820</FirstPage>
                <Occurrence Type="PID">
                  <Handle>8353504</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/hmg/2.6.820</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3sXltFSgu7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Davis DL, Russell DW. Unusual length polymorphism in human steroid 5 alpha-reductase type 2 gene (SRD5A2). Hum Mol Genet 1993;2:820.</BibUnstructured>
            </Citation>
            <Citation ID="CR49_10">
              <CitationNumber>49.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Cussenot</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AR</Initials>
                  <FamilyName>Azzouzi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Nicolaiew</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Mangin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Cormier</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Fournier</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Valeri</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Cancel-Tassin</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors</ArticleTitle>
                <JournalTitle>Eur Urol</JournalTitle>
                <VolumeID>52</VolumeID>
                <FirstPage>1082</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>17448593</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.eururo.2007.04.008</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Cussenot O, Azzouzi AR, Nicolaiew N, Mangin P, Cormier L, Fournier G, et al. Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. Eur Urol 2007;52:1082–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR50_10">
              <CitationNumber>50.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GS</Initials>
                  <FamilyName>Prins</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KS</Initials>
                  <FamilyName>Korach</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">The role of estrogens and estrogen receptors in normal prostate growth and disease</ArticleTitle>
                <JournalTitle>Steroids</JournalTitle>
                <VolumeID>73</VolumeID>
                <FirstPage>233</FirstPage>
                <LastPage>44</LastPage>
                <Occurrence Type="PID">
                  <Handle>18093629</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.steroids.2007.10.013</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXhsVyhs7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Prins GS, Korach KS. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids 2008;73:233–44.</BibUnstructured>
            </Citation>
            <Citation ID="CR51_10">
              <CitationNumber>51.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SJ</Initials>
                  <FamilyName>Ellem</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JF</Initials>
                  <FamilyName>Schmitt</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JS</Initials>
                  <FamilyName>Pedersen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Frydenberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GP</Initials>
                  <FamilyName>Risbridger</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Local aromatase expression in human prostate is altered in malignancy</ArticleTitle>
                <JournalTitle>J Clin Endocrinol Metab</JournalTitle>
                <VolumeID>89</VolumeID>
                <FirstPage>2434</FirstPage>
                <LastPage>41</LastPage>
                <Occurrence Type="PID">
                  <Handle>15126575</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/jc.2003-030933</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXjvFyrurk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ellem SJ, Schmitt JF, Pedersen JS, Frydenberg M, Risbridger GP. Local aromatase expression in human prostate is altered in malignancy. J Clin Endocrinol Metab 2004;89:2434–41.</BibUnstructured>
            </Citation>
            <Citation ID="CR52_10">
              <CitationNumber>52.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>Santen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GR</Initials>
                  <FamilyName>Petroni</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MJ</Initials>
                  <FamilyName>Fisch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CE</Initials>
                  <FamilyName>Myers</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Theodorescu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RB</Initials>
                  <FamilyName>Cohen</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>92</VolumeID>
                <FirstPage>2095</FirstPage>
                <LastPage>101</LastPage>
                <Occurrence Type="PID">
                  <Handle>11596025</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/1097-0142(20011015)92:8&lt;2095::AID-CNCR1550&gt;3.0.CO;2-Y</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXot12rtLc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Santen RJ, Petroni GR, Fisch MJ, Myers CE, Theodorescu D, Cohen RB. Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma. Cancer 2001;92:2095–101.</BibUnstructured>
            </Citation>
            <Citation ID="CR53_10">
              <CitationNumber>53.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Kaufman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>George</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WK</Initials>
                  <FamilyName>Oh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Kazanis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Manola</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PW</Initials>
                  <FamilyName>Kantoff</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Selective aromatase inhibition for patients with androgen-independent prostate carcinoma</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>95</VolumeID>
                <FirstPage>1864</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>12404279</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/cncr.10844</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XovFSqs7w%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Smith MR, Kaufman D, George D, Oh WK, Kazanis M, Manola J, et al. Selective aromatase inhibition for patients with androgen-independent prostate carcinoma. Cancer 2002;95:1864–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR54_10">
              <CitationNumber>54.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Harada</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Utsumi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Takagi</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>90</VolumeID>
                <FirstPage>11312</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>8248245</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.90.23.11312</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXitFegtL8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Harada N, Utsumi T, Takagi Y. Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. Proc Natl Acad Sci U S A 1993;90:11312–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR55_10">
              <CitationNumber>55.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Hiramatsu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Maehara</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Ozaki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Harada</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Orikasa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Sasano</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Aromatase in hyperplasia and carcinoma of the human prostate</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>31</VolumeID>
                <FirstPage>118</FirstPage>
                <LastPage>24</LastPage>
                <Occurrence Type="PID">
                  <Handle>9140125</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/(SICI)1097-0045(19970501)31:2&lt;118::AID-PROS7&gt;3.0.CO;2-J</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2s3osVyitg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hiramatsu M, Maehara I, Ozaki M, Harada N, Orikasa S, Sasano H. Aromatase in hyperplasia and carcinoma of the human prostate. Prostate 1997;31:118–24.</BibUnstructured>
            </Citation>
            <Citation ID="CR56_10">
              <CitationNumber>56.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Negri-Cesi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Poletti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Colciago</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Magni</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Martini</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Motta</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Presence of 5alpha-reductase isozymes and aromatase in human prostate cancer cells and in benign prostate hyperplastic tissue</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>34</VolumeID>
                <FirstPage>283</FirstPage>
                <LastPage>91</LastPage>
                <Occurrence Type="PID">
                  <Handle>9496903</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/(SICI)1097-0045(19980301)34:4&lt;283::AID-PROS6&gt;3.0.CO;2-I</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXhvVyns7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Negri-Cesi P, Poletti A, Colciago A, Magni P, Martini P, Motta M. Presence of 5alpha-reductase isozymes and aromatase in human prostate cancer cells and in benign prostate hyperplastic tissue. Prostate 1998;34:283–91.</BibUnstructured>
            </Citation>
            <Citation ID="CR57_10">
              <CitationNumber>57.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Tsuchiya</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Suzuki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Segawa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Fukuda</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Narita</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Shimbo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Kamoto</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Mitsumori</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Ichikawa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Ogawa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Nakamura</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Habuchi</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>24</VolumeID>
                <FirstPage>1982</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>16648498</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2005.02.9439</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28Xlt1amurw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tsuchiya N, Wang L, Suzuki H, Segawa T, Fukuda H, Narita S, et al. Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. J Clin Oncol 2006;24:1982–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR58_10">
              <CitationNumber>58.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AG</Initials>
                  <FamilyName>Latil</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Azzouzi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GS</Initials>
                  <FamilyName>Cancel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EC</Initials>
                  <FamilyName>Guillaume</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Cochan-Priollet</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PL</Initials>
                  <FamilyName>Berthon</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Cussenot</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>92</VolumeID>
                <FirstPage>1130</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>11571725</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/1097-0142(20010901)92:5&lt;1130::AID-CNCR1430&gt;3.0.CO;2-B</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXnt12mur8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Latil AG, Azzouzi R, Cancel GS, Guillaume EC, Cochan-Priollet B, Berthon PL, et al. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 2001;92:1130–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR59_10">
              <CitationNumber>59.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Cunningham</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SJ</Initials>
                  <FamilyName>Hebbring</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SK</Initials>
                  <FamilyName>McDonnell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MS</Initials>
                  <FamilyName>Cicek</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GB</Initials>
                  <FamilyName>Christensen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SJ</Initials>
                  <FamilyName>Jacobsen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JR</Initials>
                  <FamilyName>Cerhan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ML</Initials>
                  <FamilyName>Blute</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Schaid</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SN</Initials>
                  <FamilyName>Thibodeau</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Epidemiol Biomarkers Prev</JournalTitle>
                <VolumeID>16</VolumeID>
                <FirstPage>969</FirstPage>
                <LastPage>78</LastPage>
                <Occurrence Type="PID">
                  <Handle>17507624</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1055-9965.EPI-06-0767</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXltlWgtLw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Cunningham JM, Hebbring SJ, McDonnell SK, Cicek MS, Christensen GB, Wang L, et al. Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol Biomarkers Prev 2007;16:969–78.</BibUnstructured>
            </Citation>
            <Citation ID="CR60_10">
              <CitationNumber>60.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RM</Initials>
                  <FamilyName>Dos Santos</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CM</Initials>
                  <FamilyName>Jesus</FamilyName>
                  <Particle>de</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JC</Initials>
                  <FamilyName>Filho</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JC</Initials>
                  <FamilyName>Trindade</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Camargo</FamilyName>
                  <Particle>de</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CA</Initials>
                  <FamilyName>Rainho</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SR</Initials>
                  <FamilyName>Rogatto</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">PSA and androgen-related gene (AR, CYP17, and CYP19) polymorphisms and the risk of adenocarcinoma at prostate biopsy</ArticleTitle>
                <JournalTitle>DNA Cell Biol</JournalTitle>
                <VolumeID>27</VolumeID>
                <IssueID>9</IssueID>
                <FirstPage>497</FirstPage>
                <LastPage>503</LastPage>
                <Occurrence Type="PID">
                  <Handle>18491956</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1089/dna.2007.0700</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXhtVGntrrJ</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dos Santos RM, de Jesus CM, Filho JC, Trindade JC, de Camargo JL, Rainho CA, et al. PSA and androgen-related gene (AR, CYP17, and CYP19) polymorphisms and the risk of adenocarcinoma at prostate biopsy. DNA Cell Biol 2008;27(9):497–503.</BibUnstructured>
            </Citation>
            <Citation ID="CR61_10">
              <CitationNumber>61.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Modugno</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Weissfeld</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DL</Initials>
                  <FamilyName>Trump</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Zmuda</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Shea</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Cauley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RE</Initials>
                  <FamilyName>Ferrell</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>7</VolumeID>
                <FirstPage>3092</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>11595700</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXnvF2ku70%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Modugno F, Weissfeld JL, Trump DL, Zmuda JM, Shea P, Cauley JA, et al. Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin Cancer Res 2001;7:3092–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR62_10">
              <CitationNumber>62.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Onsory</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RC</Initials>
                  <FamilyName>Sobti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AI</Initials>
                  <FamilyName>Al-Badran</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Watanabe</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Shiraishi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Krishan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Mohan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Kaur</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Hormone receptor-related gene polymorphisms and prostate cancer risk in North Indian population</ArticleTitle>
                <JournalTitle>Mol Cell Biochem</JournalTitle>
                <VolumeID>314</VolumeID>
                <FirstPage>25</FirstPage>
                <LastPage>35</LastPage>
                <Occurrence Type="PID">
                  <Handle>18483761</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/s11010-008-9761-1</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXntFKntbY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Onsory K, Sobti RC, Al-Badran AI, Watanabe M, Shiraishi T, Krishan A, et al. Hormone receptor-related gene polymorphisms and prostate cancer risk in North Indian population. Mol Cell Biochem 2008;314:25–35.</BibUnstructured>
            </Citation>
            <Citation ID="CR63_10">
              <CitationNumber>63.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Sarma</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RL</Initials>
                  <FamilyName>Dunn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LA</Initials>
                  <FamilyName>Lange</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Ray</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EM</Initials>
                  <FamilyName>Lange</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KA</Initials>
                  <FamilyName>Cooney</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men’s Health Study</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>68</VolumeID>
                <FirstPage>296</FirstPage>
                <LastPage>305</LastPage>
                <Occurrence Type="PID">
                  <Handle>18163429</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.20696</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXjtFemu74%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sarma AV, Dunn RL, Lange LA, Ray A, Wang Y, Lange EM, et al. Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men’s Health Study. Prostate 2008;68:296–305.</BibUnstructured>
            </Citation>
            <Citation ID="CR64_10">
              <CitationNumber>64.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AH</Initials>
                  <FamilyName>Carey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Waterworth</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Patel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>White</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Little</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Novelli</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Franks</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Williamson</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17</ArticleTitle>
                <JournalTitle>Hum Mol Genet</JournalTitle>
                <VolumeID>3</VolumeID>
                <FirstPage>1873</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>7849715</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/hmg/3.10.1873</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXmslyitr0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P, et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 1994;3:1873–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR65_10">
              <CitationNumber>65.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Ntais</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Polycarpou</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JP</Initials>
                  <FamilyName>Ioannidis</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis</ArticleTitle>
                <JournalTitle>Cancer Epidemiol Biomarkers Prev</JournalTitle>
                <VolumeID>12</VolumeID>
                <FirstPage>120</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>12582021</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXhtVOlu7k%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ntais C, Polycarpou A, Ioannidis JP. Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2003;12:120–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR66_10">
              <CitationNumber>66.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>VW</Initials>
                  <FamilyName>Setiawan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FR</Initials>
                  <FamilyName>Schumacher</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CA</Initials>
                  <FamilyName>Haiman</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3)</ArticleTitle>
                <JournalTitle>Cancer Epidemiol Biomarkers Prev</JournalTitle>
                <VolumeID>16</VolumeID>
                <FirstPage>2237</FirstPage>
                <LastPage>46</LastPage>
                <Occurrence Type="PID">
                  <Handle>18006912</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1055-9965.EPI-07-0589</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhtlSmur3I</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Setiawan VW, Schumacher FR, Haiman CA, et al. CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev 2007;16:2237–46.</BibUnstructured>
            </Citation>
            <Citation ID="CR67_10">
              <CitationNumber>67.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Severi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>VM</Initials>
                  <FamilyName>Hayes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AA</Initials>
                  <FamilyName>Tesoriero</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Southey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HN</Initials>
                  <FamilyName>Hoang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EJ</Initials>
                  <FamilyName>Padilla</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HA</Initials>
                  <FamilyName>Morris</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DR</Initials>
                  <FamilyName>English</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RL</Initials>
                  <FamilyName>Sutherland</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Boyle</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Hopper</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GG</Initials>
                  <FamilyName>Giles</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">The rs743572 common variant in the promoter of CYP17A1 is not associated with prostate cancer risk or circulating hormonal levels</ArticleTitle>
                <JournalTitle>BJU Int</JournalTitle>
                <VolumeID>101</VolumeID>
                <FirstPage>492</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>17986287</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXktVagsbo%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1111/j.1464-410X.2007.07272.x</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Severi G, Hayes VM, Tesoriero AA, Southey MC, Hoang HN, Padilla EJ, et al. The rs743572 common variant in the promoter of CYP17A1 is not associated with prostate cancer risk or circulating hormonal levels. BJU Int 2008;101:492–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR68_10">
              <CitationNumber>68.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Nedelcheva Kristensen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EK</Initials>
                  <FamilyName>Haraldsen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KB</Initials>
                  <FamilyName>Anderson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PE</Initials>
                  <FamilyName>Lønning</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Erikstein</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Kåresen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>OS</Initials>
                  <FamilyName>Gabrielsen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AL</Initials>
                  <FamilyName>Børresen-Dale</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>59</VolumeID>
                <FirstPage>2825</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>10383140</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK1MzhtVGisQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nedelcheva Kristensen V, Haraldsen EK, Anderson KB, Lønning PE, Erikstein B, Kåresen R, et al. CYP17 and breast cancer risk: the polymorphism in the 5’ flanking area of the gene does not influence binding to Sp-1. Cancer Res 1999;59:2825–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR69_10">
              <CitationNumber>69.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JQ</Initials>
                  <FamilyName>Wang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>X</Initials>
                  <FamilyName>Gu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JC</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>XQ</Initials>
                  <FamilyName>Sun</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HT</Initials>
                  <FamilyName>Mu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ZH</Initials>
                  <FamilyName>Wei</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Li</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DQ</Initials>
                  <FamilyName>Xin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>YQ</Initials>
                  <FamilyName>Na</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Association between polymorphism of CYP17 gene and serum hormone concentrations in aged men</ArticleTitle>
                <JournalTitle>Zhonghua Nan Ke Xue</JournalTitle>
                <VolumeID>11</VolumeID>
                <FirstPage>442</FirstPage>
                <LastPage>4</LastPage>
                <Occurrence Type="PID">
                  <Handle>15999490</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XlsVyhsb4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wang JQ, Gu X, Chen JC, Sun XQ, Mu HT, Wei ZH, et al. Association between polymorphism of CYP17 gene and serum hormone concentrations in aged men. Zhonghua Nan Ke Xue 2005;11:442–4.</BibUnstructured>
            </Citation>
            <Citation ID="CR70_10">
              <CitationNumber>70.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CJ</Initials>
                  <FamilyName>Lin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JW</Initials>
                  <FamilyName>Martens</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WL</Initials>
                  <FamilyName>Miller</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">NF-1C, Sp1, and Sp3 are essential for transcription of the human gene for P450c17 (steroid 17alpha-hydroxylase/17,20 lyase) in human adrenal NCI-H295A cells</ArticleTitle>
                <JournalTitle>Mol Endocrinol</JournalTitle>
                <VolumeID>15</VolumeID>
                <FirstPage>1277</FirstPage>
                <LastPage>93</LastPage>
                <Occurrence Type="PID">
                  <Handle>11463853</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/me.15.8.1277</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXlslSgsb4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lin CJ, Martens JW, Miller WL. NF-1C, Sp1, and Sp3 are essential for transcription of the human gene for P450c17 (steroid 17alpha-hydroxylase/17,20 lyase) in human adrenal NCI-H295A cells. Mol Endocrinol 2001;15:1277–93.</BibUnstructured>
            </Citation>
            <Citation ID="CR71_10">
              <CitationNumber>71.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Rhéaume</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Lachance</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HF</Initials>
                  <FamilyName>Zhao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Breton</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Dumont</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Launoit</FamilyName>
                  <Particle>de</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Trudel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Luu-The</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Simard</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Labrie</FamilyName>
                </BibAuthorName>
                <Year>1991</Year>
                <ArticleTitle Language="En">Structure and expression of a new complementary DNA encoding the almost exclusive 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in human adrenals and gonads</ArticleTitle>
                <JournalTitle>Mol Endocrinol</JournalTitle>
                <VolumeID>5</VolumeID>
                <FirstPage>1147</FirstPage>
                <LastPage>57</LastPage>
                <Occurrence Type="PID">
                  <Handle>1944309</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1210/mend-5-8-1147</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rhéaume E, Lachance Y, Zhao HF, Breton N, Dumont M, de Launoit Y, et al. Structure and expression of a new complementary DNA encoding the almost exclusive 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in human adrenals and gonads. Mol Endocrinol 1991;5:1147–57.</BibUnstructured>
            </Citation>
            <Citation ID="CR72_10">
              <CitationNumber>72.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Stanbrough</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GJ</Initials>
                  <FamilyName>Bubley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Ross</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TR</Initials>
                  <FamilyName>Golub</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Rubin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Penning</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PG</Initials>
                  <FamilyName>Febbo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SP</Initials>
                  <FamilyName>Balk</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>66</VolumeID>
                <FirstPage>2815</FirstPage>
                <LastPage>25</LastPage>
                <Occurrence Type="PID">
                  <Handle>16510604</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-05-4000</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhvV2gt7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815–25.</BibUnstructured>
            </Citation>
            <Citation ID="CR73_10">
              <CitationNumber>73.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SA</Initials>
                  <FamilyName>Devgan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BE</Initials>
                  <FamilyName>Henderson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Yu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CY</Initials>
                  <FamilyName>Shi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Pike</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RK</Initials>
                  <FamilyName>Ross</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JK</Initials>
                  <FamilyName>Reichardt</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Genetic variation of 3 beta-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: implications for prostate cancer risk</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>33</VolumeID>
                <FirstPage>9</FirstPage>
                <LastPage>12</LastPage>
                <Occurrence Type="PID">
                  <Handle>9294620</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/(SICI)1097-0045(19970915)33:1&lt;9::AID-PROS2&gt;3.0.CO;2-H</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK2svktVeisQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Devgan SA, Henderson BE, Yu MC, Shi CY, Pike MC, Ross RK, et al. Genetic variation of 3 beta-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: implications for prostate cancer risk. Prostate 1997;33:9–12.</BibUnstructured>
            </Citation>
            <Citation ID="CR74_10">
              <CitationNumber>74.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>BL</Initials>
                  <FamilyName>Chang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SL</Initials>
                  <FamilyName>Zheng</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GA</Initials>
                  <FamilyName>Hawkins</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SD</Initials>
                  <FamilyName>Isaacs</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KE</Initials>
                  <FamilyName>Wiley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Turner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Carpten</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ER</Initials>
                  <FamilyName>Bleecker</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PC</Initials>
                  <FamilyName>Walsh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Trent</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DA</Initials>
                  <FamilyName>Meyers</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WB</Initials>
                  <FamilyName>Isaacs</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Xu</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>62</VolumeID>
                <FirstPage>1784</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>11912155</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XisVSitrg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Chang BL, Zheng SL, Hawkins GA, Isaacs SD, Wiley KE, Turner A, et al. Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility. Cancer Res 2002;62:1784–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR75_10">
              <CitationNumber>75.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Kraft</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Pharoah</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SJ</Initials>
                  <FamilyName>Chanock</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Genetic variation in the HSD17B1 gene and risk of prostate cancer</ArticleTitle>
                <JournalTitle>PLoS Genet</JournalTitle>
                <VolumeID>1</VolumeID>
                <FirstPage>68</FirstPage>
                <Occurrence Type="DOI">
                  <Handle>10.1371/journal.pgen.0010068</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kraft P, Pharoah P, Chanock SJ, et al. Genetic variation in the HSD17B1 gene and risk of prostate cancer. PLoS Genet 2005;1:68.</BibUnstructured>
            </Citation>
            <Citation ID="CR76_10">
              <CitationNumber>76.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>True</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Coleman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Hawley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CY</Initials>
                  <FamilyName>Huang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Gifford</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Coleman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TM</Initials>
                  <FamilyName>Beer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Gelmann</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Datta</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Mostaghel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Knudsen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Lange</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Vessella</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Lin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Hood</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PS</Initials>
                  <FamilyName>Nelson</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">A molecular correlate to the Gleason grading system for prostate adenocarcinoma</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>103</VolumeID>
                <FirstPage>10991</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>16829574</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.0603678103</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XnsFentL8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>True L, Coleman I, Hawley S, Huang CY, Gifford D, Coleman R, et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A 2006;103:10991–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR77_10">
              <CitationNumber>77.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Zha</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Ferdinandusse</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Hicks</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Denis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TA</Initials>
                  <FamilyName>Dunn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>Wanders</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Luo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Marzo</FamilyName>
                  <Particle>De</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WB</Initials>
                  <FamilyName>Isaacs</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>63</VolumeID>
                <FirstPage>316</FirstPage>
                <LastPage>23</LastPage>
                <Occurrence Type="PID">
                  <Handle>15599942</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.20177</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXltV2ru7g%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zha S, Ferdinandusse S, Hicks JL, Denis S, Dunn TA, Wanders RJ, et al. Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. Prostate 2005;63:316–23.</BibUnstructured>
            </Citation>
            <Citation ID="CR78_10">
              <CitationNumber>78.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>NF</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Figg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Sparreboom</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination</ArticleTitle>
                <JournalTitle>Expert Opin Drug Metab Toxicol</JournalTitle>
                <VolumeID>1</VolumeID>
                <FirstPage>429</FirstPage>
                <LastPage>45</LastPage>
                <Occurrence Type="PID">
                  <Handle>16863454</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1517/17425255.1.3.429</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhtVGjsLvJ</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Smith NF, Figg WD, Sparreboom A. Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin Drug Metab Toxicol 2005;1:429–45.</BibUnstructured>
            </Citation>
            <Citation ID="CR79_10">
              <CitationNumber>79.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Hamada</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Sissung</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DK</Initials>
                  <FamilyName>Price</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Danesi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CH</Initials>
                  <FamilyName>Chau</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Sharifi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Venzon</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Maeda</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Nagao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Sparreboom</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Mitsuya</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WL</Initials>
                  <FamilyName>Dahut</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Figg</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in Caucasian patients with androgen-independent prostatic cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>14</VolumeID>
                <FirstPage>3312</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>18519758</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-07-4118</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXmslygsL8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hamada A, Sissung T, Price DK, Danesi R, Chau CH, Sharifi N, et al. Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in Caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res 2008;14:3312–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR80_10">
              <CitationNumber>80.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>König</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Cui</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AT</Initials>
                  <FamilyName>Nies</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Keppler</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>275</VolumeID>
                <FirstPage>23161</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>10779507</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M001448200</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>König J, Cui Y, Nies AT, Keppler D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 2000;275:23161–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR81_10">
              <CitationNumber>81.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>NF</Initials>
                  <FamilyName>Smith</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Marsh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TJ</Initials>
                  <FamilyName>Scott-Horton</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Hamada</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Mielke</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Mross</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Figg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Verweij</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HL</Initials>
                  <FamilyName>McLeod</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Sparreboom</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics</ArticleTitle>
                <JournalTitle>Clin Pharmacol Ther</JournalTitle>
                <VolumeID>81</VolumeID>
                <FirstPage>76</FirstPage>
                <LastPage>82</LastPage>
                <Occurrence Type="PID">
                  <Handle>17186002</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/sj.clpt.6100011</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXht1aqsbg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Smith NF, Marsh S, Scott-Horton TJ, Hamada A, Mielke S, Mross K, et al. Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther 2007;81:76–82.</BibUnstructured>
            </Citation>
            <Citation ID="CR82_10">
              <CitationNumber>82.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SA</Initials>
                  <FamilyName>Tomlins</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DR</Initials>
                  <FamilyName>Rhodes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Perner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Dhanasekaran</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Mehra</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>XW</Initials>
                  <FamilyName>Sun</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Varambally</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>X</Initials>
                  <FamilyName>Cao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Tchinda</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Kuefer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Lee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JE</Initials>
                  <FamilyName>Montie</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RB</Initials>
                  <FamilyName>Shah</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KJ</Initials>
                  <FamilyName>Pienta</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Rubin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Chinnaiyan</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer</ArticleTitle>
                <JournalTitle>Science</JournalTitle>
                <VolumeID>310</VolumeID>
                <FirstPage>644</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>16254181</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1126/science.1117679</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhtFChsLjJ</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR83_10">
              <CitationNumber>83.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Kumar-Sinha</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SA</Initials>
                  <FamilyName>Tomlins</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Chinnaiyan</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Recurrent gene fusions in prostate cancer</ArticleTitle>
                <JournalTitle>Nat Rev Cancer</JournalTitle>
                <VolumeID>8</VolumeID>
                <FirstPage>497</FirstPage>
                <LastPage>511</LastPage>
                <Occurrence Type="PID">
                  <Handle>18563191</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nrc2402</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXnsFOkt7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008;8:497–511.</BibUnstructured>
            </Citation>
            <Citation ID="CR84_10">
              <CitationNumber>84.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Attard</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JE</Initials>
                  <FamilyName>Ang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Olmos</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JS</Initials>
                  <FamilyName>De-Bono</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug development</ArticleTitle>
                <JournalTitle>J Clin Pathol</JournalTitle>
                <VolumeID>61</VolumeID>
                <FirstPage>891</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>18495790</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1136/jcp.2008.056341</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1MXhtFyhtr8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Attard G, Ang JE, Olmos D, De-Bono JS. Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug development. J Clin Pathol 2008;61:891–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR85_10">
              <CitationNumber>85.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KG</Initials>
                  <FamilyName>Hermans</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AA</Initials>
                  <FamilyName>Bressers</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HA</Initials>
                  <FamilyName>Korput</FamilyName>
                  <Particle>van der</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NF</Initials>
                  <FamilyName>Dits</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Jenster</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Trapman</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>68</VolumeID>
                <FirstPage>3094</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>18451133</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-08-0198</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXltlSmt7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hermans KG, Bressers AA, van der Korput HA, Dits NF, Jenster G, Trapman J. Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer. Cancer Res 2008;68:3094–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR86_10">
              <CitationNumber>86.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>PH</Initials>
                  <FamilyName>Riegman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>Vlietstra</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HA</Initials>
                  <FamilyName>Korput</FamilyName>
                  <Particle>van der</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JC</Initials>
                  <FamilyName>Romijn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Trapman</FamilyName>
                </BibAuthorName>
                <Year>1991</Year>
                <ArticleTitle Language="En">Identification and androgen-regulated expression of two major human glandular kallikrein-1 (hGK-1) mRNA species</ArticleTitle>
                <JournalTitle>Mol Cell Endocrinol</JournalTitle>
                <VolumeID>76</VolumeID>
                <FirstPage>181</FirstPage>
                <LastPage>90</LastPage>
                <Occurrence Type="PID">
                  <Handle>1726490</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0303-7207(91)90272-T</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3MXisVWktLo%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Riegman PH, Vlietstra RJ, van der Korput HA, Romijn JC, Trapman J. Identification and androgen-regulated expression of two major human glandular kallikrein-1 (hGK-1) mRNA species. Mol Cell Endocrinol 1991;76:181–90.</BibUnstructured>
            </Citation>
            <Citation ID="CR87_10">
              <CitationNumber>87.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Makridakis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Akalu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JK</Initials>
                  <FamilyName>Reichardt</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Identification and characterization of somatic steroid 5alpha-reductase (SRD5A2) mutations in human prostate cancer tissue</ArticleTitle>
                <JournalTitle>Oncogene</JournalTitle>
                <VolumeID>23</VolumeID>
                <FirstPage>7399</FirstPage>
                <LastPage>405</LastPage>
                <Occurrence Type="PID">
                  <Handle>15326487</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/sj.onc.1207922</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXnslelt7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Makridakis N, Akalu A, Reichardt JK. Identification and characterization of somatic steroid 5alpha-reductase (SRD5A2) mutations in human prostate cancer tissue. Oncogene 2004;23:7399–405.</BibUnstructured>
            </Citation>
            <Citation ID="CR88_10">
              <CitationNumber>88.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Makridakis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JK</Initials>
                  <FamilyName>Reichardt</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride</ArticleTitle>
                <JournalTitle>J Mol Endocrinol</JournalTitle>
                <VolumeID>34</VolumeID>
                <FirstPage>617</FirstPage>
                <LastPage>23</LastPage>
                <Occurrence Type="PID">
                  <Handle>15956333</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1677/jme.1.01725</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXlslCju7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Makridakis N, Reichardt JK. Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride. J Mol Endocrinol 2005;34:617–23.</BibUnstructured>
            </Citation>
            <Citation ID="CR89_10">
              <CitationNumber>89.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Biancolella</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Valentini</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Minella</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Vecchione</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>D’Amico</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Chillemi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Gravina</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Bueno</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Prosperini</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Desideri</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Federici</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Bernardini</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Novelli</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines</ArticleTitle>
                <JournalTitle>Invest New Drugs</JournalTitle>
                <VolumeID>25</VolumeID>
                <FirstPage>491</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>17636412</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/s10637-007-9070-7</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXos1CitLs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Biancolella M, Valentini A, Minella D, Vecchione L, D’Amico F, Chillemi G, et al. Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines. Invest New Drugs 2007;25:491–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR90_10">
              <CitationNumber>90.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LJ</Initials>
                  <FamilyName>Schmidt</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Murillo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Tindall</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Gene expression in prostate cancer cells treated with the dual 5 alpha-reductase inhibitor dutasteride</ArticleTitle>
                <JournalTitle>J Androl</JournalTitle>
                <VolumeID>25</VolumeID>
                <FirstPage>944</FirstPage>
                <LastPage>53</LastPage>
                <Occurrence Type="PID">
                  <Handle>15477368</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhtVaitbbO</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1002/j.1939-4640.2004.tb03166.x</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Schmidt LJ, Murillo H, Tindall DJ. Gene expression in prostate cancer cells treated with the dual 5 alpha-reductase inhibitor dutasteride. J Androl 2004;25:944–53.</BibUnstructured>
            </Citation>
            <Citation ID="CR91_10">
              <CitationNumber>91.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Zhao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ML</Initials>
                  <FamilyName>Whitfield</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Xu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Botstein</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JD</Initials>
                  <FamilyName>Brooks</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Diverse effects of methylseleninic acid on the transcriptional program of human prostate cancer cells</ArticleTitle>
                <JournalTitle>Mol Biol Cell</JournalTitle>
                <VolumeID>15</VolumeID>
                <FirstPage>506</FirstPage>
                <LastPage>19</LastPage>
                <Occurrence Type="PID">
                  <Handle>14617803</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1091/mbc.E03-07-0501</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhtlGmtbw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zhao H, Whitfield ML, Xu T, Botstein D, Brooks JD. Diverse effects of methylseleninic acid on the transcriptional program of human prostate cancer cells. Mol Biol Cell 2004;15:506–19.</BibUnstructured>
            </Citation>
            <Citation ID="CR92_10">
              <CitationNumber>92.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Dong</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Zhang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AC</Initials>
                  <FamilyName>Gao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JR</Initials>
                  <FamilyName>Marshall</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Ip</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancer-specific biomarkers</ArticleTitle>
                <JournalTitle>Mol Cancer Ther</JournalTitle>
                <VolumeID>4</VolumeID>
                <FirstPage>1047</FirstPage>
                <LastPage>55</LastPage>
                <Occurrence Type="PID">
                  <Handle>16020662</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1535-7163.MCT-05-0124</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXmtFSltro%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dong Y, Zhang H, Gao AC, Marshall JR, Ip C. Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancer-specific biomarkers. Mol Cancer Ther 2005;4:1047–55.</BibUnstructured>
            </Citation>
            <Citation ID="CR93_10">
              <CitationNumber>93.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Lindström</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HO</Initials>
                  <FamilyName>Adami</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KA</Initials>
                  <FamilyName>Bälter</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Xu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SL</Initials>
                  <FamilyName>Zheng</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Stattin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Grönberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Wiklund</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Inherited variation in hormone-regulating genes and prostate cancer survival</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>13</VolumeID>
                <FirstPage>5156</FirstPage>
                <LastPage>61</LastPage>
                <Occurrence Type="PID">
                  <Handle>17785571</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-07-0669</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lindström S, Adami HO, Bälter KA, Xu J, Zheng SL, Stattin P, et al. Inherited variation in hormone-regulating genes and prostate cancer survival. Clin Cancer Res 2007;13:5156–61.</BibUnstructured>
            </Citation>
            <Citation ID="CR94_10">
              <CitationNumber>94.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RW</Initials>
                  <FamilyName>Ross</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WK</Initials>
                  <FamilyName>Oh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Xie</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Pomerantz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Nakabayashi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>O</Initials>
                  <FamilyName>Sartor</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ME</Initials>
                  <FamilyName>Taplin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MM</Initials>
                  <FamilyName>Regan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PW</Initials>
                  <FamilyName>Kantoff</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Freedman</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer</ArticleTitle>
                <JournalTitle>J Clin Oncol</JournalTitle>
                <VolumeID>26</VolumeID>
                <FirstPage>842</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>18281655</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1200/JCO.2007.13.6804</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, Sartor O, et al. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 2008;26:842–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR95_10">
              <CitationNumber>95.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Sharifi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Hamada</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Sissung</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Danesi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Venzon</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Baum</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Gulley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DK</Initials>
                  <FamilyName>Price</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WL</Initials>
                  <FamilyName>Dahut</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WD</Initials>
                  <FamilyName>Figg</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer</ArticleTitle>
                <JournalTitle>BJU Int</JournalTitle>
                <VolumeID>102</VolumeID>
                <IssueID>5</IssueID>
                <FirstPage>617</FirstPage>
                <LastPage>21</LastPage>
                <Occurrence Type="PID">
                  <Handle>18537956</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1111/j.1464-410X.2008.07629.x</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXhtFSlurjE</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sharifi N, Hamada A, Sissung T, Danesi R, Venzon D, Baum C, et al. A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU Int 2008;102(5):617–21.</BibUnstructured>
            </Citation>
            <Citation ID="CR96_10">
              <CitationNumber>96.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>VM</Initials>
                  <FamilyName>Hayes</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Severi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SA</Initials>
                  <FamilyName>Eggleton</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EJ</Initials>
                  <FamilyName>Padilla</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MC</Initials>
                  <FamilyName>Southey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RL</Initials>
                  <FamilyName>Sutherland</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Hopper</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GG</Initials>
                  <FamilyName>Giles</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">The E211 G&gt;A androgen receptor polymorphism is associated with a decreased risk of metastatic prostate cancer and androgenetic alopecia</ArticleTitle>
                <JournalTitle>Cancer Epidemiol Biomarkers Prev</JournalTitle>
                <VolumeID>14</VolumeID>
                <FirstPage>993</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>15824176</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1055-9965.EPI-04-0778</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXjtFSrsrY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hayes VM, Severi G, Eggleton SA, Padilla EJ, Southey MC, Sutherland RL, et al. The E211 G&gt;A androgen receptor polymorphism is associated with a decreased risk of metastatic prostate cancer and androgenetic alopecia. Cancer Epidemiol Biomarkers Prev 2005;14:993–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR97_10">
              <CitationNumber>97.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AW</Initials>
                  <FamilyName>Hsing</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AP</Initials>
                  <FamilyName>Chokkalingam</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>YT</Initials>
                  <FamilyName>Gao</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DA</Initials>
                  <FamilyName>Dightman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HT</Initials>
                  <FamilyName>Nguyen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Deng</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Cheng</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>IA</Initials>
                  <FamilyName>Sesterhenn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FK</Initials>
                  <FamilyName>Mostofi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FZ</Initials>
                  <FamilyName>Stanczyk</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JK</Initials>
                  <FamilyName>Reichardt</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study</ArticleTitle>
                <JournalTitle>Cancer Epidemiol Biomarkers Prev</JournalTitle>
                <VolumeID>10</VolumeID>
                <FirstPage>1077</FirstPage>
                <LastPage>82</LastPage>
                <Occurrence Type="PID">
                  <Handle>11588134</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXotVyktbc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hsing AW, Chen C, Chokkalingam AP, Gao YT, Dightman DA, Nguyen HT, et al. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2001;10:1077–82.</BibUnstructured>
            </Citation>
            <Citation ID="CR98_10">
              <CitationNumber>98.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Giwercman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Giwercman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HS</Initials>
                  <FamilyName>Pedersen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Toft</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Lundin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JP</Initials>
                  <FamilyName>Bonde</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Lundberg Giwercman</FamilyName>
                </BibAuthorName>
                <Year>2008</Year>
                <ArticleTitle Language="En">Polymorphisms in genes regulating androgen activity among prostate cancer low-risk Inuit men and high-risk Scandinavians</ArticleTitle>
                <JournalTitle>Int J Androl</JournalTitle>
                <VolumeID>31</VolumeID>
                <FirstPage>25</FirstPage>
                <LastPage>30</LastPage>
                <Occurrence Type="PID">
                  <Handle>17376218</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD1cXivVOls7c%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1111/j.1365-2605.2007.00750.x</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Giwercman C, Giwercman A, Pedersen HS, Toft G, Lundin K, Bonde JP, et al. Polymorphisms in genes regulating androgen activity among prostate cancer low-risk Inuit men and high-risk Scandinavians. Int J Androl 2008;31:25–30.</BibUnstructured>
            </Citation>
            <Citation ID="CR99_10">
              <CitationNumber>99.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Margiotti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Kim</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CL</Initials>
                  <FamilyName>Pearce</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Spera</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Novelli</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JK</Initials>
                  <FamilyName>Reichardt</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Association of the G289S single nucleotide polymorphism in the HSD17B3 gene with prostate cancer in Italian men</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>53</VolumeID>
                <FirstPage>65</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>12210481</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.10134</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38Xns1amtLg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Margiotti K, Kim E, Pearce CL, Spera E, Novelli G, Reichardt JK. Association of the G289S single nucleotide polymorphism in the HSD17B3 gene with prostate cancer in Italian men. Prostate 2002;53:65–8.</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Part>
  </Book>
</Publisher>
